ESAB (ESAB) S-1 14 Nov 22 IPO registration Financial data

Cover Page

Cover Page	9 Months Ended
	Sep. 30, 2022
Cover [Abstract]
Document Type	S-1
Entity Registrant Name	ESAB CORPORATION
Entity Filer Category	Non-accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Central Index Key	0001877322
Amendment Flag	false

CONSOLIDATED AND COMBINED CONDE

CONSOLIDATED AND COMBINED CONDENSED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	3 Months Ended		7 Months Ended	9 Months Ended
	Sep. 30, 2022	Oct. 01, 2021	Dec. 31, 2021	Sep. 30, 2022	Oct. 01, 2021
Net sales	$ 620,265	$ 605,968	$ 59,921	$ 1,929,353	$ 1,803,900
Cost of sales	410,927	398,973		1,268,212	1,178,719
Gross profit	209,338	206,995		661,141	625,181
Selling, general and administrative expense	121,668	124,104		394,026	381,225
Restructuring and other related charges	6,676	4,227		16,629	10,791
Operating income	80,994	78,664		250,486	233,165
Pension settlement gain	(3,300)	0		(3,300)	(11,208)
Interest expense (income) and other, net	12,165	(209)		19,516	(748)
Income before income taxes	72,129	78,873	11,907	234,270	245,121
Income tax expense	17,836	17,441	5,039	63,629	47,043
Net income from continuing operations	54,293	61,432		170,641	198,078
Loss from discontinued operations, net of taxes	(977)	0		(4,898)	0
Net income	53,316	61,432		165,743	198,078
Less: Income attributable to noncontrolling interest, net of taxes	962	818		2,703	2,399
Net income attributable to ESAB Corporation	$ 52,354	$ 60,614		$ 163,040	$ 195,679
Earnings (loss) per share—basic
Income from continuing operations	$ 0.88	$ 1.01		$ 2.78	$ 3.26
Loss on discontinued operations	(0.02)	0		(0.08)	0
Net income per share	0.86	1.01		2.7	3.26
Earnings (loss) per share—diluted
Income from continuing operations	0.88	1.01		2.77	3.26
Loss on discontinued operations	(0.02)	0		(0.08)	0
Net income per share—diluted	$ 0.86	$ 1.01		$ 2.69	$ 3.26
ESAB Corporation
Net sales			59,921
Cost of sales			36,435
Gross profit			23,486
Selling, general and administrative expense			11,375
Operating income			12,111
Interest expense			204
Income tax expense			5,039
Net income from continuing operations			11,907
Net income			6,868
Net income attributable to ESAB Corporation			$ 6,868

CONSOLIDATED AND COMBINED CON_2

CONSOLIDATED AND COMBINED CONDENSED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME - USD ($) $ in Thousands	3 Months Ended		7 Months Ended	9 Months Ended
	Sep. 30, 2022	Oct. 01, 2021	Dec. 31, 2021	Sep. 30, 2022	Oct. 01, 2021
Net income	$ 53,316	$ 61,432		$ 165,743	$ 198,078
Other comprehensive (loss) income:
Foreign currency translation	(98,792)	(35,901)		(245,868)	(62,493)
Unrealized gain on derivatives designated and qualifying as cash flow hedges, net of tax expense of $2,895 and $2,895	9,960	0		9,960	0
Defined benefit pension and other post-retirement plan activity, net of tax expense of $235, $0, $710 and $0	766	270		2,322	698
Other comprehensive loss	(88,066)	(35,631)		(233,586)	(61,795)
Comprehensive (loss) income	(34,750)	25,801		(67,843)	136,283
Less: comprehensive (loss) income attributable to noncontrolling interest	(181)	1,048		(693)	1,707
Comprehensive (loss) income attributable to ESAB Corporation	$ (34,569)	$ 24,753		$ (67,150)	$ 134,576
ESAB Corporation
Net income			$ 6,868
Other comprehensive (loss) income:
Foreign currency translation			(8,669)
Other comprehensive loss			(8,669)
Comprehensive (loss) income			$ (1,801)

CONSOLIDATED AND COMBINED CON_3

CONSOLIDATED AND COMBINED CONDENSED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME (Parenthetical) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended	10 Months Ended
	Sep. 30, 2022	Oct. 01, 2021	Sep. 30, 2022	Oct. 31, 2021
Statement of Comprehensive Income [Abstract]
Foreign currency translation, tax expense	$ 1,630	$ 0	$ 2,328	$ 1,491
Unrealized gain on derivatives designated and qualifying as cash flow hedges, net of tax expense	2,895		2,895
Defined benefit pension and other post-retirement plan activity, net of tax expense	$ 235	$ 0	$ 710	$ 0

CONSOLIDATED AND COMBINED CON_4

CONSOLIDATED AND COMBINED CONDENSED BALANCE SHEETS - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
CURRENT ASSETS:
Cash and cash equivalents	$ 60,634	$ 41,209
Trade receivables, less allowance for credit losses	359,956	383,496
Inventories, net	446,531	420,062
Prepaid expenses	53,174	51,949
Other current assets	67,701	67,357
Total current assets	987,996	964,073
Property, plant and equipment, net	265,185	286,278
Goodwill	1,399,661	1,532,993
Intangible assets, net	452,329	521,434
Lease assets—right of use	89,551	107,944
Other assets	345,181	48,540
Related party receivables, net		101,600
Total assets	3,539,903	3,461,262
CURRENT LIABILITIES:
Accounts payable	320,179	345,480
Current lease liability	20,323	23,110
Accrued liabilities	290,403	251,109
Total current liabilities	610,582	596,589
Noncurrent Liabilities:
Long-term debt	1,132,415	0
Other liabilities	549,381	362,945
Total liabilities	2,292,378	959,534
Equity:
Common stock—$0.001 par value—Authorized 600,000,000, 60,076,559 and 100 shares outstanding as of September 30, 2022 and December 31, 2021, respectively	60	0
Additional paid-in capital	1,857,918	0
Retained earnings	101,549	0
Former Parent's investment	0	2,921,623
Accumulated other comprehensive loss	(750,342)	(460,888)
Total ESAB Corporation equity	1,209,185	2,460,735
Noncontrolling interest	38,340	40,993
Total equity	1,247,525	2,501,728
Total liabilities and equity	$ 3,539,903	3,461,262
ESAB Corporation
CURRENT ASSETS:
Cash and cash equivalents		325
Trade receivables, less allowance for credit losses		14,880
Inventories, net		18,397
Prepaid expenses		1,722
Other current assets		1,703
Total current assets		37,027
Property, plant and equipment, net		7,369
Goodwill		75,503
Intangible assets, net		19,323
Lease assets—right of use		7,421
Other assets		795
Related party receivables, net		101,590
Total assets		249,028
CURRENT LIABILITIES:
Accounts payable		15,685
Accrued payroll		3,009
Accrued taxes		2,019
VAT payable		4,004
Current lease liability		826
Other accrued liabilities		1,113
Total current liabilities		26,656
Noncurrent Liabilities:
Deferred tax liability		5,363
Other liabilities		2,993
Non-current lease liability		6,351
Total liabilities		41,363
Equity:
Additional paid-in capital		202,515
Retained earnings		88,899
Accumulated other comprehensive loss		(83,749)
Total equity		207,665
Total liabilities and equity		$ 249,028

CONSOLIDATED AND COMBINED CON_5

CONSOLIDATED AND COMBINED CONDENSED BALANCE SHEETS (Parenthetical) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Trade receivables, allowance for doubtful accounts	$ 23,564	$ 23,912
Common Stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	600,000,000	600,000,000
Common stock, shares issued (in shares)	60,076,559	100
Common stock, shares outstanding (in shares)	60,076,559	100
ESAB Corporation
Trade receivables, allowance for doubtful accounts		$ 813

CONSOLIDATED AND COMBINED CON_6

CONSOLIDATED AND COMBINED CONDENSED STATEMENTS OF EQUITY - USD ($) $ in Thousands	Total	ESAB Corporation	Common Stock	Additional Paid in Capital	Additional Paid in Capital ESAB Corporation	Retained Earnings	Retained Earnings ESAB Corporation	Former Parent's Investment	Accumulated Other Comprehensive Loss	Accumulated Other Comprehensive Loss ESAB Corporation	Noncontrolling Interest
Beginning balance (in shares) at Dec. 31, 2020			0
Beginning balance at Dec. 31, 2020	$ 2,544,767		$ 0	$ 0		$ 0		$ 2,898,831	$ (396,203)		$ 42,139
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	58,534							57,658			876
Distributions to noncontrolling owners	(1,054)										(1,054)
Other comprehensive income (loss), net of tax (expense) benefit	(29,818)								(29,506)		(312)
Net consideration paid to Former Parent in connection with the Separation	(55,069)							(55,069)
Common stock-based award activity	1,586							1,586
Ending balance (in shares) at Apr. 02, 2021			0
Ending balance at Apr. 02, 2021	2,518,946		$ 0	0		0		2,903,006	(425,709)		41,649
Beginning balance (in shares) at Dec. 31, 2020			0
Beginning balance at Dec. 31, 2020	2,544,767		$ 0	0		0		2,898,831	(396,203)		42,139
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	198,078
Other comprehensive income (loss), net of tax (expense) benefit	(61,795)
Ending balance (in shares) at Oct. 01, 2021			0
Ending balance at Oct. 01, 2021	2,510,039		$ 0	0		0		2,926,049	(457,306)		41,296
Beginning balance (in shares) at Apr. 02, 2021			0
Beginning balance at Apr. 02, 2021	2,518,946		$ 0	0		0		2,903,006	(425,709)		41,649
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	78,112							77,407			705
Other comprehensive income (loss), net of tax (expense) benefit	3,654								4,264		(610)
Net consideration paid to Former Parent in connection with the Separation	(56,038)							(56,038)
Common stock-based award activity	1,663							1,663
Ending balance (in shares) at Jul. 02, 2021			0
Ending balance at Jul. 02, 2021	$ 2,546,337		$ 0	0		0		2,926,038	(421,445)		41,744
Beginning balance at May. 18, 2021		$ 209,466			$ 202,515		$ 82,031			$ (75,080)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income		6,868			0		6,868			0
Other comprehensive income (loss), net of tax (expense) benefit		(8,669)			0		0			(8,669)
Ending balance (in shares) at Dec. 31, 2021	100		0
Ending balance at Dec. 31, 2021	$ 2,501,728	207,665	$ 0	0	202,515	0	88,899	2,921,623	(460,888)	(83,749)	40,993
Beginning balance (in shares) at Jul. 02, 2021			0
Beginning balance at Jul. 02, 2021	2,546,337		$ 0	0		0		2,926,038	(421,445)		41,744
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	61,432							60,614			818
Distributions to noncontrolling owners	(1,496)										(1,496)
Other comprehensive income (loss), net of tax (expense) benefit	(35,631)								(35,861)		230
Net consideration paid to Former Parent in connection with the Separation	(62,305)							(62,305)
Common stock-based award activity	1,702							1,702
Ending balance (in shares) at Oct. 01, 2021			0
Ending balance at Oct. 01, 2021	$ 2,510,039		$ 0	0		0		2,926,049	(457,306)		41,296
Beginning balance (in shares) at Dec. 31, 2021	100		0
Beginning balance at Dec. 31, 2021	$ 2,501,728	207,665	$ 0	0	202,515	0	88,899	2,921,623	(460,888)	(83,749)	40,993
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	56,403							55,437			966
Distributions to noncontrolling owners	(941)										(941)
Other comprehensive income (loss), net of tax (expense) benefit	(44,403)								(43,895)		(508)
Net consideration paid to Former Parent in connection with the Separation	2,847							62,110	(59,263)
Common stock-based award activity	1,728							1,728
Ending balance (in shares) at Apr. 01, 2022			0
Ending balance at Apr. 01, 2022	$ 2,517,362		$ 0	0		0		3,040,898	(564,046)		40,510
Beginning balance (in shares) at Dec. 31, 2021	100		0
Beginning balance at Dec. 31, 2021	$ 2,501,728	$ 207,665	$ 0	0	$ 202,515	0	$ 88,899	2,921,623	(460,888)	$ (83,749)	40,993
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	165,743
Other comprehensive income (loss), net of tax (expense) benefit	$ (233,586)
Ending balance (in shares) at Sep. 30, 2022	60,076,559		60,076,559
Ending balance at Sep. 30, 2022	$ 1,247,525		$ 60	1,857,918		101,549		0	(750,342)		38,340
Beginning balance (in shares) at Apr. 01, 2022			0
Beginning balance at Apr. 01, 2022	2,517,362		$ 0	0		0		3,040,898	(564,046)		40,510
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	56,024					55,249					775
Other comprehensive income (loss), net of tax (expense) benefit	(101,118)								(99,373)		(1,745)
Dividends declared ($0.05 per share)	(3,025)					(3,025)
Net transfers from Former Parent, including Separation Adjustments	8,533							8,533
Net consideration paid to Former Parent in connection with the Separation	(1,200,000)							(1,200,000)
Issuance of common stock in connection with the Separation and reclassification of Net Investment from Former Parent (in shares)			60,034,311
Issuance of common stock in connection with the Separation and reclassification of Net Investment from Former Parent			$ 60	1,849,371				(1,849,431)
Common stock-based award activity (in shares)			9,232
Common stock-based award activity	3,627			3,627
Ending balance (in shares) at Jul. 01, 2022			60,043,543
Ending balance at Jul. 01, 2022	1,281,403		$ 60	1,852,998		52,224		0	(663,419)		39,540
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	53,316					52,354					962
Distributions to noncontrolling owners	(1,019)										(1,019)
Other comprehensive income (loss), net of tax (expense) benefit	(88,066)								(86,923)		(1,143)
Dividends declared ($0.05 per share)	(3,029)					(3,029)
Common stock-based award activity (in shares)			33,016
Common stock-based award activity	$ 4,920			4,920
Ending balance (in shares) at Sep. 30, 2022	60,076,559		60,076,559
Ending balance at Sep. 30, 2022	$ 1,247,525		$ 60	$ 1,857,918		$ 101,549		$ 0	$ (750,342)		$ 38,340

CONSOLIDATED AND COMBINED CON_7

CONSOLIDATED AND COMBINED CONDENSED STATEMENTS OF EQUITY (Parenthetical) - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2022	Jul. 01, 2022	Apr. 01, 2022	Oct. 01, 2021	Jul. 02, 2021	Apr. 02, 2021
Statement of Stockholders' Equity [Abstract]
Dividends on common stock (in dollars per share)		$ 0.05
Other comprehensive income (loss), tax (expense) benefit	$ 4,760	$ 594	$ 579	$ 0	$ 0	$ 1,491

CONSOLIDATED AND COMBINED CON_8

CONSOLIDATED AND COMBINED CONDENSED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	7 Months Ended	9 Months Ended
	Dec. 31, 2021	Sep. 30, 2022	Oct. 01, 2021
Cash flows from operating activities:
Net income		$ 165,743	$ 198,078
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization		48,699	57,305
Stock-based compensation expense		9,532	4,951
Non-cash interest expense		1,673	0
Deferred income tax		(4,725)	(2,710)
Pension settlement gain		(3,300)	(11,208)
Changes in operating assets and liabilities:
Trade receivables, net		(7,361)	(54,826)
Inventories, net		(54,757)	(105,409)
Accounts payable		(10,916)	93,382
Other operating assets and liabilities		(21,673)	12,514
Net cash provided by operating activities		122,915	192,077
Cash flows from investing activities:
Purchases of property, plant and equipment		(21,996)	(18,851)
Proceeds from sale of property, plant and equipment		4,322	1,079
Acquisition, net of cash received		0	(4,885)
Net cash used in investing activities		(17,674)	(22,657)
Cash flows from financing activities:
Proceeds from borrowings on term credit facility		1,000,000	0
Proceeds from borrowings on revolving credit facility		495,881	244
Repayments of borrowings on revolving credit facility and other		(360,000)	0
Payment of deferred financing fees and other		(4,904)	0
Payment of deferred consideration		(1,500)	0
Payment of dividends		(3,025)	0
Distributions to noncontrolling interest holders		(1,960)	(2,550)
Consideration to Former Parent in connection with the Separation		(1,200,000)	0
Transfers from (to) Former Parent, net		2,847	(173,412)
Net cash used in financing activities		(72,661)	(175,718)
Effect of foreign exchange rates on Cash and cash equivalents		(13,155)	(1,416)
Increase (decrease) in Cash and cash equivalents		19,425	(7,714)
Cash and cash equivalents, beginning of period		41,209	49,209
Cash and cash equivalents, end of period	$ 41,209	60,634	$ 41,495
ESAB Corporation [Member]
Cash flows from operating activities:
Net income	6,868
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	1,565
Deferred income tax	146
Changes in operating assets and liabilities:
Trade receivables, net	(666)
Inventories, net	(6,555)
Accounts payable	1,055
Other operating assets and liabilities	(1,422)
Net cash provided by operating activities	991
Cash flows from investing activities:
Purchases of property, plant and equipment	(783)
Proceeds from sale of property, plant and equipment	17
Net cash used in investing activities	(766)
Cash flows from financing activities:
Proceeds from short-term borrowings	52
Related party financing repayments, net	(4,323)
Net cash used in financing activities	(4,271)
Effect of foreign exchange rates on Cash and cash equivalents	(189)
Increase (decrease) in Cash and cash equivalents	(4,235)
Cash and cash equivalents, beginning of period	4,560	$ 325
Cash and cash equivalents, end of period	$ 325

Organization and Basis of Prese

Organization and Basis of Presentation	7 Months Ended	9 Months Ended
	Dec. 31, 2021	Sep. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Basis of Presentation	1. Organization and Basis of Presentation ESAB Corporation (the “Company”) is a Delaware corporation, and since its organization on May 19 2021, a wholly owned subsidiary of Colfax Corporation (“Colfax” or “Parent”). On May 19, 2021, in connection with the organization of ESAB Corporation, Colfax subscribed for 100 shares of common stock of ESAB Corporation. On March 4, 2021, Colfax announced its intention to spin off its existing Fabrication Technology business (“FabTech”) into a separate publicly-traded company. The spin-off tax-free While, subject to satisfaction of certain conditions, Colfax currently intends to effect the separation of FabTech through a distribution of shares of ESAB Corporation, Colfax has no obligation to pursue or consummate any separation of FabTech, including dispositions of its ownership interest in ESAB Corporation, by any specified date or at all. The conditions to the distribution may not be satisfied, Colfax may decide not to consummate the separation and the distribution even if the conditions are satisfied or Colfax may decide to waive one or more of these conditions and consummate the separation and distribution even if all of the conditions are not satisfied. There can be no assurance whether or when any such transaction will be consummated or as to the final terms of any such transaction. On December 14, 2021, ESAB International Holdings, a wholly owned subsidiary of the Company, was established. The Company subscribed for 100 shares of common stock of ESAB International Holdings. On December 29, 2021, in anticipation of the Distribution, certain subsidiaries of FabTech were transferred into the ownership of the Company in a common-control transaction. These subsidiaries, which operate in Peru and Colombia, are fully included in the combined financial results of the Fabrication Technology business of Colfax Corporation. The accompanying consolidated financial statements presents the historical financial position of ESAB Corporation in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”).	1. Organization and Basis of Presentation ESAB Corporation (“ESAB” or the “Company”) is a world leader in fabrication and gas control technology, providing our partners with advanced equipment, consumables, gas control equipment, robotics, and digital solutions, which enable the everyday and extraordinary work that shapes our world. The Company’s products are utilized to solve challenges in a wide range of industries, including cutting, joining and automated welding. The Company conducts its operations through two reportable segments. These segments consist of the “Americas,” which includes operations in North America and South America, and “EMEA & APAC,” which includes Europe, Middle East, India, Africa and Asia Pacific. Historically, these businesses had operated as part of Enovis Corporation’s (“Former Parent” or “Enovis”) Fabrication Technologies reportable segment. The C om th 13-week Separation from Enovis On January 31, 2022, all remaining legal entities which were part of the Fabrication Technology segment of the Former Parent along with certain entities that were part of the Corporate segment of the Former Parent became subsidiaries of ESAB through a legal entity restructuring. This reorganization resulted in the inclusion of the following items in ESAB for the three months ending April 1, 2022: • Certain operating entities that form the historical Fabrication Technology business. • Certain entities which historically have been a part of the Former Parent’s Corporate reportable segment, including components of the Former Parent’s legal, human resources, tax and other finance functions that served the entirety of the Former Parent. • Certain entities relating to the Former Parent’s previously divested Fluid Handling businesses which hold certain asbestos assets, liabilities, costs and insurance recoveries related to the asbestos obligations of these legacy industrial businesses. Refer to Note 2, “Discontinued Operations” and Note 13, “Commitments and Contingencies” for additional information. • Certain pension plan assets and liabilities due to transfer of sponsorship of two U.S. defined benefit plans and a U.S. other post-retirement benefit plan from the Former Parent to ESAB as of March 21, 2022. Refer to Note 8, “Benefit Plans” for additional information on the benefit plans transferred to ESAB. The above items, with the exception of the operating entities that form the Fabrication Technology business, were not previously included in the Company’s 2019 to 2021 historical carve-out carve-out 10-12B/A ESAB Corporation, which was incorporated on May 19, 2021, became the new ultimate parent company for the Former Parent’s Fabrication Technology business during the three months ended April 1, 2022. On April 4, 2022 (the “Distribution Date”), Colfax Corporation (“Colfax” or the “Former Parent”) completed the spin-off described above, through a tax-free, In connection with the Separation, on April 4, 2022, ESAB and Enovis entered into a separation and distribution agreement as well as various other related agreements (collectively the “Agreements”) that govern the Separation and the relationships between the parties going forward, including a transition services agreement, an employee matters agreement, a tax matters agreement, an intellectual property matters agreement, and license agreement for the ESAB Business Excellence System (“EBX”). In conjunction with the Separation on April 4, 2022, the Company entered into a credit agreement (the “Credit Agreement”). The Company drew down $1.2 billion under the Credit Agreement and used these proceeds to make payments to Enovis of $1.2 billion, which was used as part of the consideration for the contribution of certain assets and liabilities to the Company by Enovis in connection with the Separation. The Company entered into interest rate swap agreements and cross-currency swap agreements to manage exposures to currency exchange rates and interest rates arising from these credit facilities; refer to Note 9 “Debt” and Note 10 “Derivatives” for additional information. On May 12, 2022, ESAB declared a quarterly cash dividend of $0.05 per share of the Company’s common stock. The dividend of $3.0 million was paid to stockholders stockholders Russia and Ukraine Conflict The invasion of Ukraine by Russia and the sanctions imposed in response to this crisis have increased the level of economic and political uncertainty. On April 25, 2022, ESAB announced that the Company may be required to transition out of its business in Russia and are evaluating options and possible timing for this transition. ESAB continues to fulfill current contractual obligations while addressing applicable laws and regulations. For the three and nine months ended September 30, 2022, Russia represented approximately 7% and 6% of the Company’s total revenue, and approximately $7 million and $14 million of its Net Income, respectively. Russia also has approximately 6% of the Company’s total net assets excluding any goodwill allocation as of September 30, 2022. In case of the disposition of the Russia business, a portion of goodwill will need to be allocated and disposed of in the relative fair value attributable to the Russia business. Russia has a cumulative translation loss of approximately $50 million as of September 30, 2022, which could be realized upon a transition. To cover credit risks related to Russian and Ukrainian operations, ESAB increased the allowance on receivables by approximately $4 million during the nine months ended September 30, 2022. The Company is closely monitoring the developments in Ukraine and Russia. Changes in laws and regulations or other factors impacting the Company’s ability to fulfill contractual obligations could have an adverse effect on the results of operations Basis of Presentation The accompanying Consolidated and Combined Condensed Financial Statements present the Company’s historical financial position, results of operations, changes in equity and cash flows in accordance with generally accepted accounting principles in the United States of America (“GAAP”). The combined condensed financial statements for periods prior to the Separation were derived from Enovis’s consolidated financial statements and accounting records and prepared in accordance with GAAP for the preparation of carved-out Following the Separation, the consolidated financial statements include ESAB and its wholly-owned subsidiaries and no longer include any allocations of expenses from Enovis. Accordingly: • The Consolidated Balance Sheet as of September 30, 2022, consists of the consolidated balances of ESAB, while the Combined Condensed Balance Sheet as of December 31, 2021, consists of the combined balances of the former Fabrication Technology business of Enovis. • The Consolidated and Combined Condensed Statement of Operations and Statement of Comprehensive Income for the nine months ended September 30, 2022 consist of the consolidated results of ESAB for the six months ended September 30, 2022 and the combined results of the former Fabrication Technology business of Enovis and the certain entities discussed in the “Separation from Enovis” section above for the three months ended April 1, 2022. The Combined Condensed Statement of Operations and Statement of Comprehensive Income for the three and nine months ended October 1, 2021 consist of the combined results of the former Fabrication Technology business of Enovis. • The Consolidated and Combined Condensed Statement of Changes in Equity for the nine months ended September 30, 2022 consists of the consolidated activities of ESAB for the six months ended September 30, 2022 and the combined activity of the former Fabrication Technology business of Enovis and the certain entities discussed in the “Separation from Enovis” section above for the three months ended April 1, 2022. The Combined Condensed Statements of Changes in Equity for the three and nine months ended October 1, 2021 consist of the combined activity of the former Fabrication Technology business of Enovis. • The Consolidated and Combined Condensed Statement of Cash Flows for the nine months ended September 30, 2022 consists of the consolidated activities of ESAB for the six months ended September 30, 2022 and the combined activity of ESAB and the former Fabrication Technology business of Enovis and the certain entities discussed in the “Separation from Enovis” section above for the three months ended April 1, 2022. The Combined Condensed Statement of Cash Flows for the three and nine months ended October 1, 2021 consist of the combined activity of the former Fabrication Technology business of Enovis. The Consolidated and Combined Condensed Financial Statements of ESAB for the three and nine months ended October 1, 2021 and the three months ended April 1, 2022 may not be indicative of the Company’s results had it been a separate stand- alone entity throughout the periods presented, nor are the results stated herein indicative of what the Company’s financial position, results of operations and cash flows may be in the future. Prior to the Separation, the Company was dependent on the Former Parent for all of its working capital and financing requirements under Enovis’s centralized approach to cash management and financing of its operations. With the exception of cash, cash equivalents and borrowings clearly associated with ESAB and related to the Separation, financing transactions relating to the Company during the period prior to the Separation were accounted for through the Former Parent’s investment account of the Company. Accordingly, none of Enovis’s cash, cash equivalents or debt at the corporate level has been assigned to the Company in these financial statements. Former Parent’s Investment, which included retained earnings, represented Enovis’s interest in the recorded net assets of the Company. All significant transactions between the Company and the Former Parent prior to the Separation have been included in the accompanying Financial Statements. Transactions with the Former Parent are reflected in the accompanying Consolidated and Combined Condensed Statements of Equity as “Transfers from Former Parent, net” and in the accompanying Consolidated and Combined Condensed Balance Sheets within “Former Parent’s investment”. The Consolidated and Combined Condensed Financial Statements reflect, in the opinion of management, all adjustments, which consist solely of normal recurring adjustments, necessary to present fairly the Company’s financial position and results of operations as of and for the periods indicated. Intercompany transactions and accounts are eliminated in consolidation. The Company makes certain estimates and assumptions in preparing its Consolidated and Combined Condensed Financial Statements in accordance with GAAP. These estimates and assumptions affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities as of the date of the Consolidated and Combined Condensed Financial Statements and the reported amounts of revenues and expenses for the periods presented. Actual results may differ from those estimates.​​​​​​​ In the normal course of business, the Company incurs research and development costs related to new product development which are expensed as incurred and included in Selling, general and administrative expenses on the Company’s Consolidated and Combined Condensed Statements of Operations. Research and development costs were $8.0 million and $27.1 million during the three and nine months ended September 30, 2022, respectively, and $9.1 million and $28.9 million during the three and nine months ended October 1, 2021, respectively. In addition to the factors discussed elsewhere in this Form 10-Q, (“COVID-19”). These Consolidated and Combined Condensed Financial Statements included in this quarterly report have been prepared by the Company in accordance with the rules and regulations of the Securities and Exchange Commission (“SEC”) in conformity with GAAP, for the preparation of the Consolidated and Combined Condensed Financial Statements and are unaudited. Certain financial information that is normally included in annual financial statements prepared in accordance with GAAP, but that is not required for interim reporting purposes, has been omitted. The accompanying interim Consolidated and Combined Condensed Financial Statements and the related notes should be read in conjunction with the Company’s Combined Financial Statements and related notes included in the Company’s Form 10.

Summary of Significant Accounti

Summary of Significant Accounting Policies	7 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies Principles of Consolidation The Company’s Consolidated Financial Statements are prepared in accordance with U.S. GAAP and include all majority-owned subsidiaries over which the Company exercises control and, when applicable, entities or joint ventures for which the Company has a controlling financial interest or is the primary beneficiary. When protective rights, substantive rights or other factors exist, further analysis is performed in order to determine whether or not there is a controlling financial interest. The Consolidated Financial Statements reflect the assets, liabilities, revenues and expenses of consolidated subsidiaries. All significant intercompany accounts and transactions have been eliminated. Revenue Recognition The Company recognizes revenue when control of promised goods or services is transferred to the customer. The amount of revenue recognized reflects the consideration to which the Company expects to be entitled in exchange for transferring the goods or services. The Company provides a variety of products and services to its customers. Most of the Company’s contracts consist of a single, distinct performance obligation or promise to transfer goods or services to a customer. For contracts that include multiple performance obligations, we allocate the total transaction price to each performance obligation using our best estimate of the stand-alone selling price of each identified performance obligation. A significant majority of our revenue relates to the shipment of off-the-shelf Revenue recognition and billing typically occur simultaneously for contracts recognized at a point in time. Therefore we do not have material revenues in excess of customer billings or billings to customers in excess of recognized revenues. The period of benefit for the Company’s incremental costs of obtaining a contract generally have less than a one-year Taxes Collected from Customers and Remitted to Governmental Authorities The Company collects various taxes and fees as an agent in connection with the sale of products and remits these amounts to the respective taxing authorities. These taxes and fees have been presented on a net basis within Net sales in the Consolidated Statement of Operations and are recorded on the Consolidated Balance Sheet until remitted to the respective taxing authority. Cash and Cash Equivalents Cash and cash equivalents include all financial instruments purchased with an initial maturity of three months or less. Trade Receivables Trade receivables are presented net of an allowance for credit losses. The estimate of current expected credit losses on trade receivables considers historical credit loss information that is adjusted for current conditions and reasonable and supportable forecasts. Estimated credit losses are reviewed periodically by management. Inventories Inventories are valued at the lower of cost or net realizable value. Fixed manufacturing overhead costs are allocated to inventory based on normal production capacity and abnormal manufacturing activities are recognized as period costs. Cost for inventories is determined using the first-in, first-out method. The Company periodically reviews its quantities of inventories on hand and compares these amounts to the expected usage of each particular product. The Company records a charge to Cost of sales for any amounts required to reduce the carrying value of inventories to its net realizable value. Property, Plant and Equipment Property, plant and equipment, net is stated at historical cost, which includes the fair values of such assets acquired through acquisitions. Impairment of Goodwill and Indefinite-Lived Intangible Assets Goodwill represents the costs in excess of the fair value of net assets acquired through acquisitions by the Company. Indefinite-lived intangible assets consist of certain trade names. The Company evaluates the recoverability of Goodwill and its indefinite-lived trade names annually or more frequently if an event occurs or circumstances change in the interim that would more likely than not reduce the fair value of the asset below its carrying amount. The annual impairment test date elected by the Company is the first day of its fourth quarter. The Company has two reporting units and a single reporting segment. Goodwill and indefinite-lived trade names are considered to be impaired when the carrying value of a reporting unit or asset exceeds its fair value. In the evaluation of goodwill for impairment, the Company first assesses qualitative factors to determine whether it is more likely than not that the fair value of a reporting entity is less than its carrying value. If the Company determines that it is more likely than not for a reporting unit’s fair value to be greater than its carrying value, a calculation of the fair value is not performed. If the Company determines that it is more likely than not for a reporting unit’s fair value to be less than its carrying value, a calculation of the reporting unit’s fair value is performed and compared to the carrying value of that reporting unit. In certain instances, the Company may elect to forgo the qualitative assessment and proceed directly to the quantitative impairment test. If the carrying value of a reporting unit exceeds its fair value, goodwill of that reporting unit is impaired and an impairment loss is recorded equal to the excess of the reporting unit’s carrying value over its fair value. When a quantitative impairment test is needed, the Company measures fair value of reporting units based on a present value of future discounted cash flows. The discounted cash flow models indicate the fair value of the reporting units based on the present value of the cash flows that the reporting units are expected to generate in the future. Significant estimates in the discounted cash flow models include the weighted-average cost of capital, net sales and profitability of our business. No indication of impairment existed based on the Company’s evaluation for the period from inception (May 19, 2021) to December 31, 2021. No material events that would represent impairment indicators have occurred subsequent to the performance of the 2021 annual impairment test. In the evaluation of indefinite-lived trade names for impairment, the Company first assesses qualitative factors to determine whether it is more likely than not that the fair value of the trade name is less than its carrying value. If the Company determines that it is more likely than not for the trade name’s fair value to be greater than its carrying value, a calculation of the fair value is not performed. If the Company determines that it is more likely than not that the trade name’s fair value is less than its carrying value, a fair value calculation is performed and compared to the carrying value of the trade name. In certain instances, the Company may elect to forgo the qualitative assessment and proceed directly to the quantitative impairment test. If the carrying amount of the indefinite-lived trade name exceeds its fair value, an impairment loss is recognized in an amount equal to that excess. The Company measures the fair value of its indefinite-lived trade names using the “relief from royalty” method. Significant estimates in this approach include projected revenues and royalty and discount rates for each trade name evaluated. No indication of impairment existed based on the Company’s evaluation for the period from inception (May 19, 2021) to December 31, 2021. Impairment of Long-Lived Assets Other than Goodwill and Indefinite-Lived Intangible Assets Definite-lived intangible assets primarily represent acquired customer relationships. The Company generally uses a straight-line amortization method with useful lives generally ranging from ten to twenty years. The Company assesses its long-lived assets and definite-lived intangible assets for impairment whenever facts and circumstances indicate that the carrying amounts may not be fully recoverable. To analyze recoverability, the Company projects undiscounted net future cash flows over the remaining lives of such assets. If these projected cash flows are less than the carrying amounts, an impairment loss equal to the difference between the carrying amount of the asset and its fair value would be recognized, resulting in a write-down of the assets with a corresponding charge to earnings. Management determines fair value using the discounted cash flow method or other accepted valuation techniques.​​​​​​​ Income Taxes Income taxes for the Company are accounted for under the asset and liability method. Deferred income tax assets and liabilities are recognized for the future tax consequences attributable to differences between the carrying amounts of existing assets and liabilities in the Consolidated Financial Statements and their respective tax basis. Deferred income tax assets and liabilities are measured using enacted tax rates expected to be applied to taxable income in the years in which those temporary differences are expected to be recovered or settled. Deferred income tax assets are reported in Other assets in the Consolidated Balance Sheet. Deferred income tax liabilities are reported in the Consolidated Balance Sheet. The effect on deferred income tax assets and liabilities of a change in tax rates is generally recognized in Income tax expense in the period that includes the enactment date. Global Intangible Low-Taxed Valuation allowances are recorded if it is more likely than not that some portion of the deferred income tax assets will not be realized. In evaluating the need for a valuation allowance, the Company considers various factors, including the expected level of future taxable income and available tax planning strategies. Any changes in judgment about the valuation allowance are recorded through Income tax expense and are based on changes in facts and circumstances regarding realizability of deferred tax assets. The Company must presume that an income tax position taken in a tax return will be examined by the relevant tax authority and determine whether it is more likely than not that the tax position will be sustained upon examination based upon the technical merits of the position. An income tax position that meets the more-likely-than-not Use of Estimates The Company makes certain estimates and assumptions in preparing its Consolidated Financial Statements in accordance with U.S. GAAP. These estimates and assumptions affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the Consolidated Financial Statements and the reported amounts of revenues and expenses for the period presented. Actual results may differ from those estimates.

Discontinued Operations

Discontinued Operations	9 Months Ended
	Sep. 30, 2022
Discontinued Operations and Disposal Groups [Abstract]
Discontinued Operations	2. Discontinued Operations The Company holds certain asbestos-related contingencies and insurance coverages from divested businesses for which it does not have an interest in the ongoing operations. The entities that hold these assets and liabilities became subsidiaries of the Company during the three months ended April 1, 2022 in connection with the Separation. These assets and liabilities were not included in the Company’s historical Combined Financial Statements for 2021 as the Company did not have legal title to these assets, nor was the Company the legal obligor of these liabilities. The 2022 amounts reflect income, expenses, assets and liabilities historically recorded within the Former Parent’s divested businesses that were not part of Former Parent’s Fabrication Technology segment. Refer to “Note 1, Organization and Basis of Presentation” for additional information. The Company has classified asbestos-related activity in its Consolidated and Combined Condensed Statements of Operations as part of Loss from discontinued operations, net of taxes. See Note 13, “Commitments and Contingencies” for further information. Cash used in operating activities related to discontinued operations for the three and nine months ended September 30, 2022 was $5.6 million and $19.3 million, respectively.

Revenue

Revenue	7 Months Ended	9 Months Ended
	Dec. 31, 2021	Sep. 30, 2022
Revenue from Contract with Customer [Abstract]
Revenue	3. Revenue The Company develops, manufactures and supplies consumable welding and cutting products and equipment. The Company provides a wide range of products with innovative technologies to solve challenges in a range of industries, including cutting, joining and automated welding. Substantially all revenue is recognized at a point in time. The Company disaggregates its revenue into the following product groups: For the period from (In thousands) Consumables $ 50,916 Equipment 9,005 $ 59,921 There are no customers which represent more than 10% of the Company’s revenue for the period from inception (May 19, 2021) to December 31, 2021.	3. Revenue The Company develops, manufactures and supplies consumable welding and cutting products and equipment, as well as gas control equipment. The Company provides a wide range of products with innovative technologies to solve challenges in a range of industries, including cutting, joining and automated welding. Substantially all revenue is recognized at a point in time. The Company disaggregates its revenue into the following product groups: Three Months Ended Nine Months Ended September 30, October 1, September 30, 2022 October 1, (In thousands) Equipment $ 168,633 $ 192,365 $ 547,555 $ 564,971 Consumables 451,632 413,603 1,381,798 1,238,929 Total $ 620,265 $ 605,968 $ 1,929,353 $ 1,803,900 The sales mix in the above table is relatively consistent across both reportable segments. The consumables product grouping generally has less production complexity and shorter production cycles than equipment products. Given the nature of the business, the total amount of unsatisfied performance obligations with an original contract duration of greater than one year as of September 30, 2022 is immaterial. In some circumstances, customers are billed in advance of revenue recognition, resulting in contract liabilities. As of December 31, 2021 and December 31, 2020, total contract liabilities were $22.3 million and $21.6 million, respectively, and were included in Accrued liabilities on the Consolidated and Combined Condensed Balance Sheets. During the three and nine months ended September 30, 2022, revenue recognized that was included in the contract liability balance at the beginning of the year was $4.6 million and $19.0 million, respectively. During the three and nine months ended October 1, 2021, revenue recognized that was included in the contract liability balance at the beginning of the year was $3.1 million and $19.4 million, respectively. As of September 30, 2022 and October 1, 2021 total contract liabilities were $22.5 million and $19.9 million, respectively, and were included in Accrued liabilities on the Company’s Consolidated and Combined Condensed Balance Sheets. Allowance for Credit Losses A summary of the activity in the Company’s allowance for credit losses included within Trade receivables in the Consolidated and Combined Condensed Balance Sheets is as follows: Nine Months Ended September 30, 2022 Balance at Beginning of Period Charged to Write-Offs Foreign Balance at (In thousands) Allowance for credit losses $ 23,912 $ 4,756 $ (4,633 ) $ (471 ) $ 23,564

Earnings per Share from Continu

Earnings per Share from Continuing Operations	9 Months Ended
	Sep. 30, 2022
Earnings Per Share [Abstract]
Earnings per Share from Continuing Operations	4. Earnings per Share from Continuing Operations The Company has unvested share-based payment awards with a right to receive non-forfeitable two-class Three Months Ended Nine Months Ended September 30, October 1, 2021 September 30, October 1, (In thousands, except share and per share data) Computation of earnings per share from continuing operations—basic: Income from continuing operations attributable to ESAB (1) $ 53,331 $ 60,614 $ 167,938 $ 195,679 Less: distributed and undistributed earnings allocated to nonvested shares (407 ) — (1,152 ) — Income from continuing operations attributable to common $ 52,924 $ 60,614 $ 166,786 $ 195,679 Weighted-average shares of Common stock outstanding—basic 60,063,553 60,034,311 60,045,306 60,034,311 Income per share from continuing operations—basic $ 0.88 $ 1.01 $ 2.78 $ 3.26 Three Months Ended Nine Months Ended September October 1, 2021 September October 1, (In thousands, except share and per share data) Computation of earnings per share from continuing operations—diluted: Income from continuing operations attributable to common $ 52,924 $ 60,614 $ 166,786 $ 195,679 Weighted-average shares of Common stock outstanding—diluted 60,063,553 60,034,311 60,045,306 60,034,311 Net effect of potentially dilutive securities 99,668 — 80,548 — Weighted-average shares of Common stock outstanding—dilution 60,163,221 60,034,311 60,127,684 60,034,311 Net income per share from continuing operations—diluted $ 0.88 $ 1.01 $ 2.77 $ 3.26 (1) Net income from continuing operations attributable to ESAB Corporation for the respective periods is calculated using Net income from continuing operations, less Income attributable to noncontrolling interest, net of taxes, of $1.0 million and $2.7 million for the three and nine months ended Sept em

Property, Plant and Equipment,

Property, Plant and Equipment, Net	7 Months Ended
	Dec. 31, 2021
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment, Net	4. Property, Plant and Equipment, Net Property, Plant and Equipment, consisted of the following: Depreciable Life December 31, (In years) (In thousands) Land n/a $ 1,459 Buildings and improvements 5-40 4,530 Machinery and equipment 3-15 8,453 14,442 Accumulated depreciation (7,073 ) $ 7,369 Depreciation expense for the period from inception (May 19, 2021) to December 31, 2021 was $0.6 million.

Income Taxes

Income Taxes	7 Months Ended	9 Months Ended
	Dec. 31, 2021	Sep. 30, 2022
Income Tax Disclosure [Abstract]
Income Taxes	8. Income Taxes Income before income taxes and Income tax expense consisted of the following: For the period from May 19, 2021 to (In thousands) Income before income taxes: Domestic operations $ — Foreign operations 11,907 $ 11,907 Income tax expense: Current: Federal $ — State — Foreign 4,893 4,893 Deferred: Domestic operations — Foreign operations 146 146 $ 5,039 The Company’s Income tax expense differs from the amount that would be computed by applying the U.S. federal statutory rate as follows: For the period from (In thousands) Taxes calculated at the U.S. federal statutory rate $ 2,500 Effect of tax rates on international operations 1,112 Withholding taxes 1,427 Income tax expense $ 5,039 Deferred income taxes, net reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to reverse. The significant components of deferred tax assets and liabilities are as follows:​​​​​​​ December 31, (In thousands) Deferred tax assets: Expenses currently not deductible $ 3,423 Deferred tax liabilities: Depreciation and amortization $ (8,064 ) Inventory (722 ) Total deferred tax liabilities $ (8,786 ) Total deferred tax liabilities, net $ (5,363 ) For the year ended December 31, 2021, all undistributed earnings of the Company’s foreign subsidiaries, which are indefinitely reinvested outside the U.S., were provisionally estimated to be $17.7 million. The Company records a liability for unrecognized income tax benefits for the amount of benefit included in its previously filed income tax returns and in its financial results expected to be included in income tax returns to be filed for periods through the date of its Consolidated Financial Statements for income tax positions for which it is not more likely than not to be sustained upon examination by the respective taxing authority. The gross unrecognized tax benefit (inclusive of associated interest and penalties) at inception (May 19, 2021) and December 31, 2021 was $2.9 million. The Company is routinely examined by tax authorities around the world. Tax examinations remain in process in Peru. In Peru, tax years dating back to 2012 remain subject to examination. The Company’s total unrecognized tax benefits were $2.9 million as of December 31, 2021, inclusive of $0.8 million of interest and penalties and are included within Other liabilities on the Consolidated Balance Sheet. Due to the difficulty in predicting with reasonable certainty when tax audits will be fully resolved and closed, the range of reasonably possible significant increases or decreases in the liability for unrecognized tax benefits that may occur within the next 12 months is difficult to ascertain. Currently, the Company estimates that it is reasonably possible that the expiration of various statutes of limitations, resolution of tax audits and court decisions may reduce its tax expense in the next 12 months, the Company does not expect any such reduction to be material.	5. Income Taxes During the three and nine months ended September 30, 2022, Income from continuing operations before income taxes was $72.1 million and $234.3 million, respectively, while Income tax expense was $17.8 million and $63.6 million, respectively. The effective tax rate was 24.7% and 27.2% for the three and nine months ended September 30, 2022, respectively. The effective tax rates differed from the 2022 U.S. federal statutory rate of 21% primarily due to the impact of withholding taxes and non-deductible During the three and nine months ended October 1, 2021, Income from continuing operations before income taxes was $78.9 million and $245.1 million, respectively, while Income tax expense was $17.4 million and $47.0 million, respectively. The effective tax rate was 22.1% and 19.2% for the three and nine months ended October 1, 2021, respectively. The effective tax rates differed from the 2021 U.S. federal statutory rate of 21% primarily due to the recognition of discrete tax benefits as a result of audit settlements that occurred in first nine months of 2021. Additionally, the Company’s foreign earnings in the first nine months of 2021 were taxed at lower rates than the U.S federal statutory rate.

Inventories, Net

Inventories, Net	7 Months Ended	9 Months Ended
	Dec. 31, 2021	Sep. 30, 2022
Inventory Disclosure [Abstract]
Inventories, Net	5. Inventories, Net Inventories, net consisted of the following: December 31, (In thousands) Raw materials $ 6,946 Work in process 453 Finished goods 11,935 19,334 Less: allowance for excess, slow-moving and obsolete inventory (937 ) $ 18,397	6. Inventories, Net Inventories, net consisted of the following: September 30, 2022 December 31, 2021 (In thousands) Raw materials $ 152,316 $ 148,376 Work in process 45,099 39,595 Finished goods 286,132 268,831 483,547 456,802 LIFO reserve (204 ) 1,129 Less: allowance for excess, slow-moving and obsolete inventory (36,812 ) (37,869 ) $ 446,531 $ 420,062

Leases

Leases	7 Months Ended
	Dec. 31, 2021
Leases [Abstract]
Leases	6. Leases The Company leases certain office spaces and vehicles. Leases with an initial term of twelve months or less are not recorded on the balance sheet. Most leases include renewal options, which can extend the lease term into the future. The Company determines the lease term by assuming options that are reasonably certain of being renewed will be exercised. Certain of the Company’s leases include rental payments adjusted for inflation. The right-of-use The following table presents the maturity of our operating lease liabilities as of December 31, 2021: December 31, (In thousands) Future lease payments by year: 2022 $ 1,090 2023 961 2024 835 2025 530 2026 551 Thereafter 5,110 Total 9,077 Less: present value discount (1,900 ) Present value of lease liabilities $ 7,177 Weighted-average remaining lease term (in years): Operating leases 11.49 Weighted-average discount rate: Operating leases 3.9 %

Accrued and Other Liabilities

Accrued and Other Liabilities	9 Months Ended
	Sep. 30, 2022
Accrued Liabilities [Abstract]
Accrued and Other Liabilities	7. Accrued and Other Liabilities Accrued and Other liabilities in the Consolidated and Combined Condensed Balance Sheets consisted of the following: Current Noncurrent Current Noncurrent September 30, 2022 December 31, 2021 In thousands) A cc $ 57,813 $ 169,839 $ 58,920 $ 203,760 Compensation and related benefits 70,203 62,299 74,587 62,215 Asbestos liability 34,841 236,757 — — Contract liability 22,475 — 22,265 — Lease liabilit 20,323 72,060 23,110 88,777 Warranty liability 13,721 — 14,954 — Third-party commissions 14,964 — 16,130 — Restructuring liability 6,747 100 7,834 275 Other 49,316 8,326 33,309 7,918 $ 290,403 $ 549,381 $ 251,109 $ 362,945 Accrued Warranty Liability A summary of the activity in the Company’s warranty liability included in Accrued liabilities in the Company’s Consolidated and Combined Condensed Balance Sheets is as follows: Nine Months Ended September 30, 2022 October 1, 2021 (In thousands) Warranty liability, beginning of period $ 14,954 $ 14,022 Accrued warranty expense 4,367 5,661 Changes in estimates related to pre-existing 2,190 1,401 Cost of warranty service work performed (6,815 ) (5,626 ) Foreign exchange translation effect (975 ) (256 ) Warranty liability, end of period $ 13,721 $ 15,202 Accrued Restructuring Liability The Company’s restructuring programs include a series of actions to reduce the structural costs of the Company. A summary of the activity in the Company’s restructuring liability included in Accrued liabilities and Other liabilities in the Consolidated and Combined Condensed Balance Sheets is as follows: Nine Months Ended September 30, 2022 Balance at Charges Payments Foreign Balance at (In thousands) Restructuring and other related charges: Americas Termination benefits (1) $ 2,044 $ 1,691 $ (2,708 ) $ (7 ) $ 1,020 Facility closure costs and other (2) 50 10,022 (10,013 ) — 59 Subtotal 2,094 11,713 (12,721 ) (7 ) 1,079 Non-cash (2) (37 ) Segment Total 11,676 EMEA & APAC Termination benefits (1) 5,774 2,622 (2,879 ) (174 ) 5,343 Facility closure costs and other (2) 241 2,331 (2,131 ) (16 ) 425 Subtotal 6,015 4,953 (5,010 ) (190 ) 5,768 Non-cash (2) — Segment Total 4,953 Total $ 8,109 16,666 $ (17,731 ) $ (197 ) $ 6,847 Non-cash (2) (37 ) Total Provision $ 16,629 (1) Includes severance and other termination benefits, including outplacement services. (2) Includes the cost of relocating associates, relocating equipment, lease termination expense and other costs in connection with the closure and optimization of facilities and product lines.

Goodwill and Intangible Assets

Goodwill and Intangible Assets	7 Months Ended
	Dec. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets	7. Goodwill and Intangible Assets The following table summarizes Goodwill activity for the period from inception (May 19, 2021) to December 31, 2021: December 31, 2021 (In thousands) Balance, May 19, 2021 $ 79,954 Impact of foreign currency translation (4,451 ) Balance, December 31, 2021 $ 75,503 The following table summarizes the Company’s Intangible assets, excluding Goodwill: December 31, 2021 Gross Accumulated (In thousands) Indefinite-lived intangible assets Trade names $ 4,124 $ — Definite-lived intangible assets Software 1,509 (1,280 ) Acquired customer relationships 27,402 (12,432 ) $ 33,035 $ (13,712 ) Amortization expense for the period from inception (May 19, 2021) to December 31, 2021 was $1.0 million. See Note 2, “Summary of Significant Accounting Policies” for discussion regarding impairment of Intangible assets.

Benefit Plans

Benefit Plans	9 Months Ended
	Sep. 30, 2022
Retirement Benefits [Abstract]
Benefit Plans	8. Benefit Plans The Company sponsors various defined benefit plans and other post-retirement benefits plans, including health and life insurance, for certain eligible employees or former employees. As part of the Separation, certain U.S. defined benefit and other post-retirement plans, formerly sponsored by the Former Parent, were transferred to the Company as of March 21, 2022. As a result of the transfer, the related net plan obligations of approximately $10.6 million are included within the Company’s Consolidated Balance Sheet at September 30, 2022. The transferred plans include a defined benefit pension plan with assets of $201.2 million and projected benefit liabilities of $200.6 million and two unfunded defined benefit and other post-retirement benefit plans with liabilities of $11.7 million, all of which were recorded in the financial statements of the Former Parent at December 31, 2021. The pretax net unrecognized pension and other post-retirement benefit cost included in Accumulated other comprehensive loss at April 1, 2022 for the transferred plans was approximately $50 million. The net plan assets and obligations are presented within Compensation and related benefits in Note 7, “Accrued and Other Liabilities”. The Former Parent offered both funded and unfunded noncontributory defined benefit pension plans in the U.S. that are shared amongst its businesses, including the Company prior to becoming plan sponsor. The participation of the Company’s employees and retirees in this plan is reflected in the Company’s historical Combined Financial Statements as though it participated in a multiemployer plan with the Former Parent. As a result, a proportionate share of the cost associated with this defined benefit plan is reflected in the Company’s historical Combined Financial Statements, while any assets and liabilities associated with this defined benefit plan were retained by the Former Parent and were not recorded on the Company’s historical Combined Financial Statements, prior to the Separation. Net periodic pension benefit income related to this Former Parent-sponsored plan was allocated to the Company based on the Company’s share of total Former Parent headcount and is reflected within Interest expense (income) and other, net, in the Consolidated and Combined Condensed Statements of Operations for the three months ended April 1, 2022 and nine months ended October 1, 2021. Net periodic benefit cost of the Company’s defined benefit pension plan was $0.2 million and $0.6 million for the three and nine months ended September 30, 2022, respectively, and was $0.7 million and $1.4 million for the three and nine months ended October 1, 2021, respectively. In the nine months ended September 30, 2022, contributions of $0.8 million to U.S. pension plans and $3.5 million to foreign pension plans were made. In the three months ended September 30, 2022, the Company recognized a pension settlement gain of $3.3 million related to the completed buy-out

Debt

Debt	9 Months Ended
	Sep. 30, 2022
Debt Disclosure [Abstract]
Debt	9. Debt Long-term debt consisted of the following: September 30, 2022 (In thousands) Term loans $ 997,415 Revolving credit facilities 135,000 Long-term debt $ 1,132,415 Term Loans and Revolving Credit Facility On April 4, 2022, the Company entered into a credit agreement (as amended and restated from time-to-time, • A $750 million revolving credit facility (the “Revolving Facility”) with a maturity date of April 4, 2027; • A Term A-1 A-1 • A $600 million 364-day A-2 The Revolving Facility contains a $300 million letter of credit foreign currency sublimit and a $50 million swing line loan sub-facility. On April 4, 2022, the Company drew down $1.2 billion available under the credit facilities made up of (i) $200 million under the Revolving Facility, (ii) $400 million under the Term Loan A-1 A-2 On June 28, 2022, the Company amended and restated the Credit Agreement by entering into Amendment No. 2 to Credit Agreement (“Credit Agreement Amendment”). The Credit Agreement Amendment provides for a $600 million term loan facility (the “Term Loan A-3 A-1 A-2 A-3 A-2 The Credit Agreement contains customary covenants limiting the ability of the Company and its subsidiaries to, among other things, incur debt or liens, merge or consolidate with others, dispose of assets, make investments or pay dividends. In addition, the Credit Agreement contains financial covenants requiring the Company to maintain (i) a maximum total leverage ratio of not more than 4.00:1.00, with step-downs to, commencing with the fiscal quarter ending June 30, 2023, 3.75:1.00, and commencing with the fiscal quarter ending June 30, 2024, 3.50:1.00, and (ii) a minimum interest coverage ratio of 3.00:1:00. The Credit Agreement contains various events of default (including failure to comply with the covenants under the Credit Agreement and related agreements) and upon an event of default the lenders may, subject to various customary cure rights, require the immediate payment of all amounts outstanding under the Term Facilities and the Revolving Facility. Certain U.S. subsidiaries of the Company have agreed to guarantee the obligations of the Company under the Credit Agreement. Loans made under the Term Facilities will bear interest, at the election of the Company, at either the base rate (as defined in the Credit Agreement) or at the term Secured Overnight Financing Rate (“SOFR”) rate plus an adjustment (as defined in the Credit Agreement), in each case, plus the applicable interest rate margin. Loans made under the Revolving Facility will bear interest, at the election of the Company, at either the base rate or, (i) in the case of loans denominated in dollars, the term SOFR rate plus an adjustment or the daily simple SOFR plus an adjustment, (ii) in the case of loans denominated in euros, the adjusted Euro Interbank Offered Rate (“EURIBOR”) rate and, (iii) in the case of loans denominated in sterling, Sterling Overnight Index Average (“SONIA”) plus an adjustment (as all such rates are defined in the Second Credit Agreement), in each case, plus the applicable interest rate margin. The applicable interest rate margin changes based upon the Company’s total leverage ratio (ranging from 1.125% to 1.750% or in the case of the base rate margin, 0.125% to 0.750%). Each swing line loan denominated in dollars will bear interest at the base rate plus the applicable interest rate margin. To manage exposures to currency exchange rates and interest rates arising in Long-term debt, the Company entered into interest rate and cross currency swap agreements during the three months ended September 30, 2022, refer to Note 10, “Derivatives” for additional information. As of September 30, 2022, the weighted-average interest rate of borrowings under the Credit Agreement was 3.82%, including the net impact from the interest rate swaps and excluding accretion of deferred financing fees, and there was $615 million available on the Revolving Facility. Other Indebtedness In addition to the debt agreements discussed above, the Company also has the ability to incur $50 million of indebtedness pursuant to certain uncommitted credit lines, consisting of an uncommitted credit line that the Company currently has in place that the Company has used from time to time in the past for short-term working capital needs. The Company is party to letter of credit facilities with an aggregate capacity of $107.5 million. Total letters of credit of $29.4 million were outstanding as of September 30, 2022. Deferred Financing Fees In total, the Company had deferred financing fees of $3.9 million included in its Consolidated Balance Sheet as of September 30, 2022, which will be charged to Interest expense (income) and other, net, using the straight-line method. The costs associated with the Term Facilities will be amortized over the contractual term of the Term Facilities and the costs associated with the Revolving Facility will be amortized over the life of the Credit Agreement. Of the $3.9 million, $1.3 million of deferred financing fees relating to the Revolving Facility are included in Other assets and $2.6 million of deferred financing fees relating to the Term Facilities are recorded as a contra-liability within Long-term debt.

Derivatives

Derivatives	9 Months Ended
	Sep. 30, 2022
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivatives	10. Derivatives The Company uses derivative instruments to manage exposures to currency exchange rates and interest rates arising in connection with Long-term debt and the normal course of business. The Company has established policies and procedures that govern the risk management of these exposures. Both at inception and on an ongoing basis, the derivative instruments that qualify for hedge accounting are assessed as to their effectiveness, when applicable. The Company is subject to the credit risk of counterparties to derivative instruments. Counterparties include a number of major banks and financial institutions. None of the concentrations of risk with an individual counterparty was considered significant as of September 30, 2022. The Company does not expect any counterparties to fail to meet their obligations. The Company records derivatives in the Consolidated and Combined Condensed Balance Sheets at fair value. Cash Flow Hedges On July 14, 2022, the Company entered into two interest rate swap agreements to manage interest rate risk exposure. The aggregate notional amount of these contracts is $600 million and they mature in April 2025. These interest rate swap agreements utilized by the Company effectively modify the Company’s exposure to interest rate risk by converting a portion of the Company’s floating-rate debt to a fixed rate of 3.293%, plus a spread, thus reducing the impact of interest-rate changes on future interest expense. The applicable spread may vary between 1.125% to 1.750%, depending on the total leverage ratio of the Company. The spread is 1.500% as of September 30, 2022. These agreements involve the receipt of floating-rate amounts in exchange for fixed-rate interest payments over the life of the agreement without an exchange of the underlying principal amount. The above interest rate swap agreements are designated and qualify as a cash flow hedge and as such, the gain or loss on the derivative instrument due to the change in fair value is reported as a component of accumulated other comprehensive income (“AOCI”) and reclassified into earnings in the same period or periods during which the hedged transaction affects earnings. If a derivative is deemed to be ineffective, the change in fair value of the derivative is recognized directly in earnings. As of September 30, 2022 the cash flow hedges were perfectly effective. The cash inflows and outflows associated with the Company’s interest rate swap agreements designated as cash flow hedges are classified in cash flows from operating activities in the accompanying Consolidated and Combined Condensed Statements of Cash Flows. The Company expects a gain of $4.2 million, net of tax, related to interest rate swap agreements to be reclassified from AOCI to earnings over the next 12 months as the hedged transactions are realized. The expected gain to be reclassified is based on current forward rates in active markets as of September 30, 2022. The effects of designated cash flow hedges on the Company’s Consolidated and Combined Condensed Statements of Operations consisted of the following: Three Months Ended Derivative type Loss recognized in the Consolidated and Combined Condensed Statements of Operations: September 30, 2022 (In thousands) Interest rate swap agreements Interest expense (income) and other, net $ 1,045 Net Investment Hedges On July 22, 2022 the Company entered into two cross-currency swap agreements to partially hedge its net investment in its Euro-denominated subsidiaries against adverse movements in exchange rates between the U.S. dollar and the Euro. In addition, the cross-currency swap agreements are agreements to exchange fixed-rate payments in U.S. dollar for fixed-rate payments in Euro and are designated and qualify as a net investment hedge. These contracts have a Euro aggregate notional amount of approximately €270 million and a U.S. dollar aggregate notional amount of $275 million at September 30, 2022, and they mature in April 2025. The changes in the spot rate of these instruments are recorded in AOCI in equity, partially offsetting the foreign currency translation adjustment of the Company’s related net investment that is also recorded in AOCI. The Company uses the spot method of assessing hedge effectiveness and as such, the initial value of the hedge components excluded from the assessment of effectiveness is recognized in the Interest expense (income) and other, net line item in the Consolidated and Combined Condensed Statement of Operations under a systematic and rational method over the life of the cross-currency swap agreements. Any ineffective portions of net investment hedges are reclassified from accumulated other comprehensive income (loss) into earnings during the period of change. As of September 30, 2022 the net investment hedges were perfectly effective. The cash inflows and outflows associated with the excluded components of the Company’s cross-currency swap agreements designated as net investment hedges are classified in operating activities in the accompanying Consolidated and Combined Condensed Statements of Cash Flows. The table below shows the fair value of the derivatives recognized in the Consolidated Balance Sheet and also the effects of designated hedges on AOCI: September 30, 2022 Designated as hedging instruments: Other Assets Total gain recognized in AOCI, net of tax (In thousands) Cross currency swap agreements $ 9,578 $ 7,421 Interest rate swap agreements 12,855 9,960 Total $ 22,433 $ 17,381 Derivatives Not Designated as Hedging Instruments The Company has certain foreign currency contracts that are not designated as hedges. As of September 30, 2022 and December 31, 2021, the Company had foreign currency contracts related to purchases and sales with notional values of $183.1 million and $180.8 million, respectively. The Company recognized the following in its Consolidated and Combined Condensed Financial Statements related to its derivative instruments not designated in a hedging relationship: Three Months Ended Nine Months Ended Foreign currency contracts September 30, 2022 October 1, 2021 September 30, 2022 October 1, 2021 (In thousands) Change in unrealized gains (losses) $ 279 $ (2,374 ) $ 469 $ (6,108 ) Realized loss (1) (740 ) (1,383 ) (17,235 ) (1,472 ) (1) The nine months ended September 30, 2022 includes realized losses relating to certain corporate entities contributed to ESAB Corporation which are reflected within Interest expense (income) and other, net, in the Consolidated and Combined Condensed Statements of Operations during the three months ended April 1, 2022. See Note 1, “Organization and Basis of Presentation” for additional details. These realized losses are offset by unrealized gains which are also reflected within Interest expense (income) and other, net, in the Consolidated and Combined Condensed Statements of Operations during the three months ended April 1, 2022.

Fair Value Measurements

Fair Value Measurements	7 Months Ended	9 Months Ended
	Dec. 31, 2021	Sep. 30, 2022
Fair Value Disclosures [Abstract]
Fair Value Measurements	9. Financial Instruments and Fair Value Measurements The Company utilizes fair value measurement guidance prescribed by accounting standards to value its financial instruments. The guidance establishes a fair value hierarchy based on the inputs used to measure fair value. This hierarchy prioritizes the inputs into three broad levels as follows: Level One: Level Two: Level Three: A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. The carrying values of financial instruments, including Trade receivables, other receivables and Accounts payable, approximate their fair values due to their short-term maturities. The estimated fair values may not represent actual values of the financial instruments that could be realized as of the balance sheet date or that will be realized in the future. A summary of the Company’s assets and liabilities that are measured at fair value on a recurring basis for each fair value hierarchy level for the periods presented is as follows: December 31, 2021 Level Level Level Total (In thousands) Assets: Foreign currency contracts - not designated as hedges (1) $ — $ 509 $ — $ 509 Liabilities: Foreign currency contracts - not designated as hedges (2) $ — $ 30 $ — $ 30 (1) Included within other current assets in the Consolidated Balance Sheet. (2) Included within other accrued liabilities in the Consolidated Balance Sheet. There were no transfers in or out of Level One, Two or Three during the period from inception (May 19, 2021) to December 31, 2021. Foreign Currency Contracts The Company periodically enters into foreign currency derivative contracts including foreign currency swaps and forward contracts to mitigate exchange rate risk. Commodity derivative contracts can be used to manage costs of raw materials used in the Company’s production processes. Foreign currency contracts are measured using broker quotations or observable market transactions in either listed or over-the-counter The Company recognized the following in its Consolidated Financial Statements related to its derivative instruments: For the period from (In thousands) Contracts Not Designated in a Hedge Relationship: Foreign Currency Contracts Changes in unrealized gain $ 478 Realized loss $ (2,624 )	11. Fair Value Measurements The carrying values of financial instruments, including Trade receivables and Accounts payable, approximate their fair values due to their short-term maturities. The estimated fair values may not represent actual values of the financial instruments that could be realized as of the balance sheet date or that will be realized in the future. A summary of the Company’s assets and liabilities that are measured at fair value for each fair value hierarchy level for the periods presented is as follows: September 30, 2022 Level One Level Two Level Three Total (In thousands) Assets: Cash equivalents $ 6,633 $ — $ — $ 6,633 Foreign currency contracts—not designated as hedges (1) — 2,432 — 2,432 Cross currency swap agreements — 9,578 — 9,578 Interest rate swap agreements — 12,855 — 12,855 Deferred compensation plans — 2,189 — 2,189 $ 6,633 $ 27,054 $ — $ 33,687 Liabilities: Foreign currency contracts—not designated as hedges (2) $ — $ 2,153 $ — $ 2,153 Deferred compensation plans — 2,189 — 2,189 $ — $ 4,342 $ — $ 4,342 (1) Included within Other Current Assets in the Consolidated Balance Sheet. (2) Included within Accrued Liabilities in the Consolidated Balance Sheet. December 31, 2021 Level One Level Two Level Three Total (In thousands) Assets: Cash equivalents $ 8,133 $ — $ — $ 8,133 Foreign currency contracts—not designated as hedges (1) — 2,487 — 2,487 $ 8,133 $ 2,487 $ — $ 10,620 Liabilities: Foreign currency contracts—not designated as hedges (2) $ — $ 2,309 $ — $ 2,309 (1) Included within Other Current Assets in the Consolidated and Combined Condensed Balance Sheet. (2) Included within Accrued Liabilities in the Consolidated and Combined Condensed Balance Sheet. The Company measures the fair value of foreign currency contracts, cross currency swap agreements and interest rate swap agreements using Level Two inputs based on observable spot and forward rates in active markets. Additionally, the fair value of derivatives designated in hedging relationships includes a credit valuation adjustment to appropriately incorporate nonperformance risk for the Company and the respective counterparty. For the three months ended September 30, 2022, the impact of the credit valuation adjustment on the Company’s derivatives is immaterial. Refer to Note 10, “Derivatives” for additional information. There were no transfers in or out of Level One, Two or Three during the nine months ended September 30, 2022.

Equity

Equity	9 Months Ended
	Sep. 30, 2022
Equity [Abstract]
Equity	12. Equity Accumulated Other Comprehensive Loss The following tables present the changes in the balances of each component of Accumulated other comprehensive loss including reclassifications out of Accumulated other comprehensive loss for the nine months ended September 30, 2022 and October 1, 2021. All amounts are net of tax and noncontrolling interest, if any. Accumulated Other Comprehensive Loss Components Net Unrecognized Pension And Other Post- Retirement Benefit Cost Foreign Currency Translation Adjustment Gains on Net Investment Hedges Gains on Cash Flow Hedges Total (In thousands) Balance at December 31, 2021 $ (21,196 ) $ (439,692 ) $ — $ — $ (460,888 ) Other comprehensive income (loss) before reclassifications: Foreign currency translation adjustment 490 (45,171 ) — — (44,681 ) Other comprehensive income (loss) before reclassifications 490 (45,171 ) — — (44,681 ) Amounts reclassified from Accumulated other comprehensive loss (1) 786 — — — 786 Amounts contributed by Former Parent (2) (50,504 ) (8,759 ) — — (59,263 ) Net current period Other comprehensive loss (49,228 ) (53,930 ) — — (103,158 ) Balance at April 1, 2022 $ (70,424 ) $ (493,622 ) $ — $ — $ (564,046 ) Other comprehensive income (loss) before reclassifications: Foreign currency translation adjustment (1,354 ) (98,789 ) — — (100,143 ) Other comprehensive income (loss) before reclassifications (1,354 ) (98,789 ) — — (100,143 ) Amounts reclassified from Accumulated other comprehensive loss (1) 770 — — — 770 Net current period Other comprehensive loss (584 ) (98,789 ) — — (99,373 ) Balance at July 1, 2022 $ (71,008 ) $ (592,411 ) $ — $ — $ (663,419 ) Other comprehensive income (loss) before reclassifications: Foreign currency translation adjustment 3,685 (108,755 ) 7,421 — (97,649 ) Unrealized gain on cash flow hedges — — — 9,150 9,150 Other comprehensive income (loss) before reclassifications 3,685 (108,755 ) 7,421 9,150 (88,499 ) Amounts reclassified from Accumulated other comprehensive loss (1)(3) 766 — — 810 1,576 Net current period Other comprehensive income (loss) 4,451 (108,755 ) 7,421 9,960 (86,923 ) Balance at September 30, 2022 $ (66,557 ) $ (701,166 ) $ 7,421 $ 9,960 $ (750,342 ) (1) The amounts on this line within the Net Unrecognized Pension And Other Post-Retirement Benefit Cost column are included in the computation of net periodic benefit cost. See Note 8, “Benefit Plans” for additional details. (2) Includes unrecognized pension and other post-retirement costs and accumulated currency translation adjustments of certain entities which were part of the Corporate segment of the Former Parent and were transferred to ESAB Corporation in anticipation of the Separation. See Note 1, “Organization and Basis of Presentation” for more information on the entities contributed from the Former Parent. (3) During the three months ended September 30, 2022, the amount on this line within the Gains on Cash Flow Hedge column, is a component of Interest expense (income) and other, net . Accumulated Other Comprehensive Loss Components Net Unrecognized Pension And Other Post- Retirement Benefit Cost Foreign Currency Translation Adjustment Total (In thousands) Balance at December 31, 2020 $ (29,378 ) $ (366,825 ) $ (396,203 ) Other comprehensive income (loss) before reclassifications: Foreign currency translation adjustment 712 (30,438 ) (29,726 ) Other comprehensive income (loss) before reclassifications 712 (30,438 ) (29,726 ) Amounts reclassified from Accumulated other comprehensive loss (1) 220 — 220 Net current period Other comprehensive income (loss) 932 (30,438 ) (29,506 ) Balance at April 2, 2021 $ (28,446 ) $ (397,263 ) $ (425,709 ) Other comprehensive income (loss) before reclassifications: Foreign currency translation adjustment (126 ) 4,182 4,056 Other comprehensive income (loss) before reclassifications (126 ) 4,182 4,056 Amounts reclassified from Accumulated other comprehensive loss (1) 208 — 208 Net current period Other comprehensive income (loss) 82 4,182 4,264 Balance at July 2, 2021 $ (28,364 ) $ (393,081 ) $ (421,445 ) Other comprehensive income (loss) before reclassifications: Foreign currency translation adjustment 508 (36,639 ) (36,131 ) Other comprehensive income (loss) before reclassifications 508 (36,639 ) (36,131 ) Amounts reclassified from Accumulated other comprehensive loss (1) 270 — 270 Net current period Other comprehensive income (loss) 778 (36,639 ) (35,861 ) Balance at October 1, 2021 $ (27,586 ) $ (429,720 ) $ (457,306 ) (1) Included in the computation of net periodic benefit cost. See Note 8, “Benefit Plans” for additional details. Share-Based Payments Prior to the Separation, certain employees of the Company participated in the Former Parent’s stock-based compensation plans. In connection with the Separation, the Company adopted the 2022 Omnibus Incentive Plan (the “Stock Plan”) and outstanding equity awards of the Former Parent held by ESAB employees were converted into or replaced with awards of ESAB common stock under the Stock Plan based on the “concentration method,” and as adjusted to maintain the economic value before and after the Distribution Date using the relative fair market value of the Former Parent and ESAB common stock. For each equity award holder, the intent was to maintain the economic value of the equity awards immediately before and after the Distribution. The terms of the equity awards, such as the award period, exercisability and vesting schedule, as applicable, generally continued unchanged. Other than converted or replacement equity awards of ESAB issued in replacement of the Former Parent’s restricted stock units (“RSUs”) and stock options, the terms of the converted or replacement equity awards of ESAB (e.g., vesting date and expiration date) continued unchanged. Incremental stock-based compensation expense recorded as a result of this equity award conversion was $2.6 million and is being recognized over the remaining service period. Stock-based compensation expenses incurred by the Company were $4.2 million and $9.5 million during the three and nine months ended September 30, 2022, respectively, and $1.7 million and $5.0 million during the three and nine months ended October 1, 2021, respectively.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	13. Commitments and Contingencies Asbestos Contingencies Certain entities that became subsidiaries of ESAB Corporation in connection with the Separation are the legal obligor for certain asbestos obligations including long-term asbestos insurance assets, long-term asbestos insurance receivables, accrued asbestos liabilities, long-term asbestos liabilities, asbestos indemnity expenses, asbestos-related defense costs and asbestos insurance recoveries related to the asbestos obligations from the Former Parent’s other legacy industrial businesses. As a result, the Company holds certain asbestos-related contingencies and insurance coverages. These subsidiaries are each one of many defendants in a large number of lawsuits that claim personal injury as a result of exposure to asbestos from products manufactured or used with components that are alleged to have contained asbestos. Such components were acquired from third-party suppliers, and were not manufactured by any of the Company’s, or Former Parent’s, subsidiaries nor were the subsidiaries, producers or direct suppliers of asbestos. The manufactured products that are alleged to have contained or used asbestos generally were provided to meet the specifications of the subsidiaries’ customers, including the U.S. Navy. The subsidiaries settle asbestos claims for amounts the Company considers reasonable given the facts and circumstances of each claim. The annual average settlement payment per asbestos claimant has fluctuated during the past several years while the number of cases has steadily declined. The Company expects such fluctuations to continue in the future based upon, among other things, the number and type of claims settled in a particular period and the jurisdictions in which such claims arise. To date, the majority of settled claims have been dismissed for no payment. The Company has classified asbestos-related activity in Loss from discontinued operations in the Consolidated and Combined Condensed Statements of Operations. This is consistent with the Former Parent’s classification on the basis that, pursuant to the purchase agreement from the Former Parent’s Fluid Handling business divestiture, the Former Parent retained its asbestos-related contingencies and insurance coverages. However, as the Former Parent did not retain an interest in the ongoing operations of the business subject to the contingencies, asbestos-related activity was classified as part of Loss from discontinued operations, net of taxes in the Condensed Consolidated Statements of Operations of the Former Parent. The Company has projected each subsidiary’s future asbestos-related liability costs with regard to pending and future unasserted claims based upon the Nicholson methodology. The Nicholson methodology is a standard approach used by experts and has been accepted by numerous courts. Consistent with the Former Parent, it is ESAB’s policy to record a liability for asbestos-related liability costs for the longest period of time that ESAB management can reasonably estimate. The Company believes that it can reasonably estimate the asbestos-related liability for pending and future claims that will be resolved in the next 15 years and has recorded that liability as its best estimate. While it is reasonably possible that the subsidiaries will incur costs after this period, the Company does not believe the reasonably possible loss or a range of reasonably possible losses is estimable at the current time. Accordingly, no accrual has been recorded for any costs which may be paid after the next 15 years. Defense costs associated with asbestos-related liabilities as well as costs incurred related to efforts to recover insurance from the subsidiaries’ insurers are expensed as incurred. Each subsidiary has separate insurance coverage acquired prior to Company ownership. The Company estimates the insurance assets for each subsidiary based upon the applicable policy language, expected recoveries and allocation methodologies, and law pertaining to the affected subsidiary’s insurance policies. Asbestos-related claims activity since December 31, 2021 is as follows: Nine Months Ended September 30, 2022 (Number of claims) Claims unresolved, beginning of period 14,559 Claims filed (1) 3,285 Claims resolved (2) (3,677 ) Claims unresolved, end of period 14,167 (1) Claims filed include all asbestos claims for which notification has been received or a file has been opened. (2) Claims resolved include all asbestos claims that have been settled, dismissed or that are in the process of being settled or dismissed based upon agreements or understandings in place with counsel for the claimants. The Company’s Consolidated Balance Sheet included the following amounts related to asbestos-related litigation: September 30, 2022 (In thousands) Long-term asbestos insurance asset (1) $ 216,760 Long-term asbestos insurance receivable (1) 23,291 Accrued asbestos liability (2) 34,841 Long-term asbestos liability (3) 236,757 (1) Included in Other assets in the Consolidated Balance Sheet. (2) Represents current accruals for probable and reasonably estimable asbestos-related liability costs that the Company believes the subsidiaries will pay, and unpaid legal costs related to defending themselves against asbestos-related liability claims and legal action against the Company’s insurers, which is included in Accrued liabilities in the Consolidated Balance Sheet. (3) Included in Other liabilities in the Consolidated Balance Sheet. Management’s analyses are based on currently known facts and assumptions. Projecting future events, such as new claims to be filed each year, the average cost of resolving each claim, coverage issues among layers of insurers, the method in which losses will be allocated to the various insurance policies, interpretation of the effect on coverage of various policy terms and limits and their interrelationships, the continuing solvency of various insurance companies, the amount of remaining insurance available, as well as the numerous uncertainties inherent in asbestos litigation could cause the actual liabilities and insurance recoveries to be higher or lower than those projected or recorded which could materially affect the Company’s financial condition, results of operations or cash flow. General Litigation The Company is involved in various pending legal proceedings arising out of the ordinary course of the Company’s business. None of these legal proceedings is expected to have a material adverse effect on the financial condition, results of operations or cash flow of the Company. With respect to these proceedings, and the litigation and claims described in the preceding paragraphs, management of the Company believes that it will either prevail, has adequate insurance coverage or has established appropriate accruals to cover potential liabilities. Legal costs related to proceedings or claims are recorded when incurred. Other costs that management estimates may be paid related to the claims are accrued when the liability is considered probable and the amount can be reasonably estimated. There can be no assurance, however, as to the ultimate outcome of any of these matters, and if all or substantially all of these legal proceedings were to be determined adverse to the Company, there could be a material adverse effect on the financial condition, results of operations or cash flow of the Company.

Segment Information

Segment Information	9 Months Ended
	Sep. 30, 2022
Segment Reporting [Abstract]
Segment Information	14. Segment Information ESAB is a world leader in fabrication and gas control technology, providing our partners with advanced equipment, consumables, gas control equipment, robotics, and digital solutions, which enable the everyday and extraordinary work that shapes our world. The Company’s products are utilized to solve challenges in a wide range of industries, including cutting, joining and automated welding. The Company’s management evaluates the operating results of each of its reportable segments based upon Net sales and segment Adjusted EBITA, which represents operating income excluding the impact of Restructuring and other related charges, acquisition-related intangible asset amortization, and separation costs. The Company’s segment results were as follows: Three Months Ended Nine Months Ended September 30, 2022 October 1, 2021 September 30, 2022 October 1, 2021 (In thousands) Net sales: Americas $ 281,361 $ 260,005 $ 844,741 $ 739,793 EMEA & APAC 338,904 345,963 1,084,612 1,064,107 $ 620,265 $ 605,968 $ 1,929,353 $ 1,803,900 Adjusted EBITA (1) Americas $ 43,200 $ 38,627 $ 128,860 $ 102,665 EMEA & APAC 53,520 54,093 169,769 169,785 $ 96,720 $ 92,720 $ 298,629 $ 272,450 (1) The following is a reconciliation of Operating income to Adjusted EBITA: Three Months Ended Nine Months Ended September 30, 2022 October 1, 2021 September 30, 2022 October 1, 2021 (In thousands) Operating income $ 80,994 $ 78,664 $ 250,486 $ 233,165 Restructuring and other related charges 6,676 4,227 16,629 10,791 Separation costs (1) 1,834 713 8,923 819 Amortization of acquired intangibles (2) 7,216 8,934 22,523 27,130 Other (3) — 182 68 545 Adjusted EBITA $ 96,720 $ 92,720 $ 298,629 $ 272,450 (1) Includes non-recurring (2) Included within the Selling, general and administrative expense line withing the Consolidated and Combined Condensed Statements of Operations. (3) Relates to certain items included within the Interest expense (income) and other, net line within the Consolidated and Combined Condensed Statements of Operations.

Related Party Transactions

Related Party Transactions	7 Months Ended	9 Months Ended
	Dec. 31, 2021	Sep. 30, 2022
Related Party Transactions [Abstract]
Related Party Transactions	10. Related Party Transactions The Parent allocates management charges to the Company for corporate services and license fees. Management charges of $4.0 million were recognized within Selling, general and administrative expense on the Consolidated Statement of Operations for the period from inception (May 19, 2021) to December 31, 2021. The Company participates in Colfax’s corporate cash sweep program and has executed certain financing transactions with other entities under common control. As a result of these transactions, the Company has a balance due from related parties of $101.6 million as of December 31, 2021. Interest is accrued on these balances at a rate of London Inter-Bank Offered Rate less 0.25%.	15. Related Party Transactions Related Party Agreements On April 4, 2022, in connection with the Separation, the Company entered into several agreements with Enovis that govern the Separation and provide a framework for the relationship between the parties going forward including a separation and distribution agreement, a transition services agreement, tax matters agreement, employee matters agreements, a stockholder’s and registration rights agreement, an intellectual property matters agreement and an Enovis Growth Excellence Business System (“EGX”) license agreement. The Separation and Distribution Agreement The Company entered into a separation and distribution agreement (the “Separation Agreement”) with Enovis immediately prior to the distribution of the Company’s common stock to Enovis stockholders. The Separation Agreement sets forth the Company’s agreements with Enovis regarding the principal actions to be taken in connection with the Separation. The Separation Agreement contains provisions that, among other things, relate to (i) assets, liabilities and contracts to be transferred, assumed and assigned to each of ESAB and Enovis as part of the Separation, (ii) cash distribution made to Enovis in partial consideration of the transfer of ESAB Assets to the Company in connection with the Separation, and (iii) cross-indemnities principally designed to place financial responsibility for the obligations and liabilities of ESAB’s business with ESAB and financial responsibility for the obligations and liabilities of Enovis’s remaining business with Enovis. Transition Services Agreement The transition services agreement (“TSA”) sets forth the terms and conditions pursuant to which the Company and its subsidiaries and Enovis and its subsidiaries will provide to each other various services. The services to be provided include human resources, payroll, certain information technology services, treasury services and financial reporting services. The charges for the transition services generally are expected to allow the providing company to fully recover all internal and external costs and expenses it actually incurs in connection with providing the service (including a reasonable allocation of overhead) provided in the manner and at a level substantially consistent with that provided by the respective providing company immediately preceding the Distribution Date. Tax Matters Agreement The tax matters agreement governs the Company’s and Enovis’s respective rights, responsibilities and obligations after the Separation with respect to tax liabilities and benefits, tax attributes, the preparation and filing of tax returns, the control of audits and other tax proceedings and certain other matters regarding taxes. Employee Matters Agreement The employee matters agreement sets forth, among other things, the allocation of assets, liabilities and responsibilities relating to employee compensation and benefit plans and programs and other related matters in connection with the Separation, including the treatment of outstanding equity and other incentive awards and certain retirement and welfare benefit obligations. Stockholders and Registration Rights Agreement The stockholders and registration rights agreement sets forth the right of the stockholders when requiring the Company to facilitate the resale of shares. Intellectual Property Matters Agreement The intellectual property matters agreement sets forth the terms and conditions pursuant to which Enovis and the Company have mutually granted certain personal, generally irrevocable, non-exclusive, EGX License Agreement The EGX License Agreement sets forth the terms and conditions pursuant to which Enovis has granted a royalty-free, non- Allocated Expenses The Company had historically operated as part of the Former Parent and not as a stand-alone company. Accordingly, the Former Parent allocated certain shared costs to the Company that are reflected as expenses in these financial statements. These amounts included, but were not limited to, items such as general management and executive oversight, compliance, human resources, procurement, and legal functions and financial management, including public company reporting, consolidated tax filings and tax planning. Management considered the allocation methodologies used by the Former Parent to be reasonable and to appropriately reflect the related expenses attributable to the Company for purposes of the carve-out addition, the expenses reflected in the financial statements may not be indicative of expenses the Company will incur in the future. Allocation methodologies utilized include the Company’s relative share of total Former Parent revenues and headcount. All of the Company’s transactions with the Former Parent were considered to be financing transactions, which are presented as Transfers from (to) Former Parent, net in the accompanying Consolidated and Combined Condensed Statements of Cash Flows. The Company had no stock-based compensation plans prior to the Separation; however, certain employees of the Company participated in the Former Parent’s stock-based compensation plans, which provided for the grants of stock options and RSUs among other types of awards. The expense associated with the Company’s employees who participated in the plans of the Former Parent was allocated to the Company in the accompanying Consolidated and Combined Condensed Statements of Operations through the date of Separation. The Company’s allocated expenses from the Former Parent were $6.0 million for the three months ended April 1, 2022 and $5.0 million and $19.6 million for the three and nine months ended October 1, 2021, respectively. Following the Separation, the company independently incurs expenses as a stand-alone company and corporate expenses from Enovis were no longer allocated to the Company; therefore, no related amounts were reflected on the Company’s financial statements for the six months ended September 30, 2022. Refer to Note 8, “Benefit Plans,” for allocations of net periodic benefit associated with a Former Parent sponsored benefit plan for the three months ended April 1, 2022 and nine months ended October 1, 2021.

Subsequent Events

Subsequent Events	9 Months Ended
	Sep. 30, 2022
Subsequent Events [Abstract]
Subsequent Events	16. Subsequent Events The dividend of $3.0 million included in Accrued liabilities in the Consolidated Balance Sheet at September 30, 2022 was paid on October 14, 2022, to stockholders of record as of September 30, 2022. On October 14, 2022, the Company completed the acquisition of Ohio Medical, LLC, a global leader in oxygen regulators and central gas systems, for approximately $127 million. The Company expects an additional cash tax benefit with a net present value of $15 million. During the twelve months ended August 31, 2022, Ohio Medical, LLC generated over $45 million of sales.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	7 Months Ended	9 Months Ended
	Dec. 31, 2021	Sep. 30, 2022
Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation The Company’s Consolidated Financial Statements are prepared in accordance with U.S. GAAP and include all majority-owned subsidiaries over which the Company exercises control and, when applicable, entities or joint ventures for which the Company has a controlling financial interest or is the primary beneficiary. When protective rights, substantive rights or other factors exist, further analysis is performed in order to determine whether or not there is a controlling financial interest. The Consolidated Financial Statements reflect the assets, liabilities, revenues and expenses of consolidated subsidiaries. All significant intercompany accounts and transactions have been eliminated.	On January 31, 2022, all remaining legal entities which were part of the Fabrication Technology segment of the Former Parent along with certain entities that were part of the Corporate segment of the Former Parent became subsidiaries of ESAB through a legal entity restructuring. This reorganization resulted in the inclusion of the following items in ESAB for the three months ending April 1, 2022: • Certain operating entities that form the historical Fabrication Technology business. • Certain entities which historically have been a part of the Former Parent’s Corporate reportable segment, including components of the Former Parent’s legal, human resources, tax and other finance functions that served the entirety of the Former Parent. • Certain entities relating to the Former Parent’s previously divested Fluid Handling businesses which hold certain asbestos assets, liabilities, costs and insurance recoveries related to the asbestos obligations of these legacy industrial businesses. Refer to Note 2, “Discontinued Operations” and Note 13, “Commitments and Contingencies” for additional information. • Certain pension plan assets and liabilities due to transfer of sponsorship of two U.S. defined benefit plans and a U.S. other post-retirement benefit plan from the Former Parent to ESAB as of March 21, 2022. Refer to Note 8, “Benefit Plans” for additional information on the benefit plans transferred to ESAB. The above items, with the exception of the operating entities that form the Fabrication Technology business, were not previously included in the Company’s 2019 to 2021 historical carve-out carve-out 10-12B/A ESAB Corporation, which was incorporated on May 19, 2021, became the new ultimate parent company for the Former Parent’s Fabrication Technology business during the three months ended April 1, 2022. On April 4, 2022 (the “Distribution Date”), Colfax Corporation (“Colfax” or the “Former Parent”) completed the spin-off described above, through a tax-free, In connection with the Separation, on April 4, 2022, ESAB and Enovis entered into a separation and distribution agreement as well as various other related agreements (collectively the “Agreements”) that govern the Separation and the relationships between the parties going forward, including a transition services agreement, an employee matters agreement, a tax matters agreement, an intellectual property matters agreement, and license agreement for the ESAB Business Excellence System (“EBX”). In conjunction with the Separation on April 4, 2022, the Company entered into a credit agreement (the “Credit Agreement”). The Company drew down $1.2 billion under the Credit Agreement and used these proceeds to make payments to Enovis of $1.2 billion, which was used as part of the consideration for the contribution of certain assets and liabilities to the Company by Enovis in connection with the Separation. The Company entered into interest rate swap agreements and cross-currency swap agreements to manage exposures to currency exchange rates and interest rates arising from these credit facilities; refer to Note 9 “Debt” and Note 10 “Derivatives” for additional information. On May 12, 2022, ESAB declared a quarterly cash dividend of $0.05 per share of the Company’s common stock. The dividend of $3.0 million was paid to stockholders stockholders
Revenue Recognition	Revenue Recognition The Company recognizes revenue when control of promised goods or services is transferred to the customer. The amount of revenue recognized reflects the consideration to which the Company expects to be entitled in exchange for transferring the goods or services. The Company provides a variety of products and services to its customers. Most of the Company’s contracts consist of a single, distinct performance obligation or promise to transfer goods or services to a customer. For contracts that include multiple performance obligations, we allocate the total transaction price to each performance obligation using our best estimate of the stand-alone selling price of each identified performance obligation. A significant majority of our revenue relates to the shipment of off-the-shelf Revenue recognition and billing typically occur simultaneously for contracts recognized at a point in time. Therefore we do not have material revenues in excess of customer billings or billings to customers in excess of recognized revenues. The period of benefit for the Company’s incremental costs of obtaining a contract generally have less than a one-year
Taxes Collected from Customers and Remitted to Governmental Authorities	Taxes Collected from Customers and Remitted to Governmental Authorities The Company collects various taxes and fees as an agent in connection with the sale of products and remits these amounts to the respective taxing authorities. These taxes and fees have been presented on a net basis within Net sales in the Consolidated Statement of Operations and are recorded on the Consolidated Balance Sheet until remitted to the respective taxing authority.
Cash and Cash Equivalents	Cash and Cash Equivalents Cash and cash equivalents include all financial instruments purchased with an initial maturity of three months or less.
Trade Receivables	Trade Receivables Trade receivables are presented net of an allowance for credit losses. The estimate of current expected credit losses on trade receivables considers historical credit loss information that is adjusted for current conditions and reasonable and supportable forecasts. Estimated credit losses are reviewed periodically by management.
Inventories	Inventories Inventories are valued at the lower of cost or net realizable value. Fixed manufacturing overhead costs are allocated to inventory based on normal production capacity and abnormal manufacturing activities are recognized as period costs. Cost for inventories is determined using the first-in, first-out method. The Company periodically reviews its quantities of inventories on hand and compares these amounts to the expected usage of each particular product. The Company records a charge to Cost of sales for any amounts required to reduce the carrying value of inventories to its net realizable value.
Property, Plant and Equipment	Property, Plant and Equipment Property, plant and equipment, net is stated at historical cost, which includes the fair values of such assets acquired through acquisitions.
Impairment of Goodwill and Indefinite-Lived Intangible Assets	Impairment of Goodwill and Indefinite-Lived Intangible Assets Goodwill represents the costs in excess of the fair value of net assets acquired through acquisitions by the Company. Indefinite-lived intangible assets consist of certain trade names. The Company evaluates the recoverability of Goodwill and its indefinite-lived trade names annually or more frequently if an event occurs or circumstances change in the interim that would more likely than not reduce the fair value of the asset below its carrying amount. The annual impairment test date elected by the Company is the first day of its fourth quarter. The Company has two reporting units and a single reporting segment. Goodwill and indefinite-lived trade names are considered to be impaired when the carrying value of a reporting unit or asset exceeds its fair value. In the evaluation of goodwill for impairment, the Company first assesses qualitative factors to determine whether it is more likely than not that the fair value of a reporting entity is less than its carrying value. If the Company determines that it is more likely than not for a reporting unit’s fair value to be greater than its carrying value, a calculation of the fair value is not performed. If the Company determines that it is more likely than not for a reporting unit’s fair value to be less than its carrying value, a calculation of the reporting unit’s fair value is performed and compared to the carrying value of that reporting unit. In certain instances, the Company may elect to forgo the qualitative assessment and proceed directly to the quantitative impairment test. If the carrying value of a reporting unit exceeds its fair value, goodwill of that reporting unit is impaired and an impairment loss is recorded equal to the excess of the reporting unit’s carrying value over its fair value. When a quantitative impairment test is needed, the Company measures fair value of reporting units based on a present value of future discounted cash flows. The discounted cash flow models indicate the fair value of the reporting units based on the present value of the cash flows that the reporting units are expected to generate in the future. Significant estimates in the discounted cash flow models include the weighted-average cost of capital, net sales and profitability of our business. No indication of impairment existed based on the Company’s evaluation for the period from inception (May 19, 2021) to December 31, 2021. No material events that would represent impairment indicators have occurred subsequent to the performance of the 2021 annual impairment test. In the evaluation of indefinite-lived trade names for impairment, the Company first assesses qualitative factors to determine whether it is more likely than not that the fair value of the trade name is less than its carrying value. If the Company determines that it is more likely than not for the trade name’s fair value to be greater than its carrying value, a calculation of the fair value is not performed. If the Company determines that it is more likely than not that the trade name’s fair value is less than its carrying value, a fair value calculation is performed and compared to the carrying value of the trade name. In certain instances, the Company may elect to forgo the qualitative assessment and proceed directly to the quantitative impairment test. If the carrying amount of the indefinite-lived trade name exceeds its fair value, an impairment loss is recognized in an amount equal to that excess. The Company measures the fair value of its indefinite-lived trade names using the “relief from royalty” method. Significant estimates in this approach include projected revenues and royalty and discount rates for each trade name evaluated. No indication of impairment existed based on the Company’s evaluation for the period from inception (May 19, 2021) to December 31, 2021.
Impairment of Long-Lived Assets Other than Goodwill and Indefinite-Lived Intangible Assets	Impairment of Long-Lived Assets Other than Goodwill and Indefinite-Lived Intangible Assets Definite-lived intangible assets primarily represent acquired customer relationships. The Company generally uses a straight-line amortization method with useful lives generally ranging from ten to twenty years.
Income Taxes	Income Taxes Income taxes for the Company are accounted for under the asset and liability method. Deferred income tax assets and liabilities are recognized for the future tax consequences attributable to differences between the carrying amounts of existing assets and liabilities in the Consolidated Financial Statements and their respective tax basis. Deferred income tax assets and liabilities are measured using enacted tax rates expected to be applied to taxable income in the years in which those temporary differences are expected to be recovered or settled. Deferred income tax assets are reported in Other assets in the Consolidated Balance Sheet. Deferred income tax liabilities are reported in the Consolidated Balance Sheet. The effect on deferred income tax assets and liabilities of a change in tax rates is generally recognized in Income tax expense in the period that includes the enactment date. Global Intangible Low-Taxed Valuation allowances are recorded if it is more likely than not that some portion of the deferred income tax assets will not be realized. In evaluating the need for a valuation allowance, the Company considers various factors, including the expected level of future taxable income and available tax planning strategies. Any changes in judgment about the valuation allowance are recorded through Income tax expense and are based on changes in facts and circumstances regarding realizability of deferred tax assets. The Company must presume that an income tax position taken in a tax return will be examined by the relevant tax authority and determine whether it is more likely than not that the tax position will be sustained upon examination based upon the technical merits of the position. An income tax position that meets the more-likely-than-not
Use of Estimates	Use of Estimates The Company makes certain estimates and assumptions in preparing its Consolidated Financial Statements in accordance with U.S. GAAP. These estimates and assumptions affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the Consolidated Financial Statements and the reported amounts of revenues and expenses for the period presented. Actual results may differ from those estimates.	The Company makes certain estimates and assumptions in preparing its Consolidated and Combined Condensed Financial Statements in accordance with GAAP. These estimates and assumptions affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities as of the date of the Consolidated and Combined Condensed Financial Statements and the reported amounts of revenues and expenses for the periods presented. Actual results may differ from those estimates.​​​​​​​

Organization and Basis of Pre_2

Organization and Basis of Presentation (Policies)	7 Months Ended	9 Months Ended
	Dec. 31, 2021	Sep. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Fiscal Period		The C om th 13-week
Separation from Enovis	Principles of Consolidation The Company’s Consolidated Financial Statements are prepared in accordance with U.S. GAAP and include all majority-owned subsidiaries over which the Company exercises control and, when applicable, entities or joint ventures for which the Company has a controlling financial interest or is the primary beneficiary. When protective rights, substantive rights or other factors exist, further analysis is performed in order to determine whether or not there is a controlling financial interest. The Consolidated Financial Statements reflect the assets, liabilities, revenues and expenses of consolidated subsidiaries. All significant intercompany accounts and transactions have been eliminated.	On January 31, 2022, all remaining legal entities which were part of the Fabrication Technology segment of the Former Parent along with certain entities that were part of the Corporate segment of the Former Parent became subsidiaries of ESAB through a legal entity restructuring. This reorganization resulted in the inclusion of the following items in ESAB for the three months ending April 1, 2022: • Certain operating entities that form the historical Fabrication Technology business. • Certain entities which historically have been a part of the Former Parent’s Corporate reportable segment, including components of the Former Parent’s legal, human resources, tax and other finance functions that served the entirety of the Former Parent. • Certain entities relating to the Former Parent’s previously divested Fluid Handling businesses which hold certain asbestos assets, liabilities, costs and insurance recoveries related to the asbestos obligations of these legacy industrial businesses. Refer to Note 2, “Discontinued Operations” and Note 13, “Commitments and Contingencies” for additional information. • Certain pension plan assets and liabilities due to transfer of sponsorship of two U.S. defined benefit plans and a U.S. other post-retirement benefit plan from the Former Parent to ESAB as of March 21, 2022. Refer to Note 8, “Benefit Plans” for additional information on the benefit plans transferred to ESAB. The above items, with the exception of the operating entities that form the Fabrication Technology business, were not previously included in the Company’s 2019 to 2021 historical carve-out carve-out 10-12B/A ESAB Corporation, which was incorporated on May 19, 2021, became the new ultimate parent company for the Former Parent’s Fabrication Technology business during the three months ended April 1, 2022. On April 4, 2022 (the “Distribution Date”), Colfax Corporation (“Colfax” or the “Former Parent”) completed the spin-off described above, through a tax-free, In connection with the Separation, on April 4, 2022, ESAB and Enovis entered into a separation and distribution agreement as well as various other related agreements (collectively the “Agreements”) that govern the Separation and the relationships between the parties going forward, including a transition services agreement, an employee matters agreement, a tax matters agreement, an intellectual property matters agreement, and license agreement for the ESAB Business Excellence System (“EBX”). In conjunction with the Separation on April 4, 2022, the Company entered into a credit agreement (the “Credit Agreement”). The Company drew down $1.2 billion under the Credit Agreement and used these proceeds to make payments to Enovis of $1.2 billion, which was used as part of the consideration for the contribution of certain assets and liabilities to the Company by Enovis in connection with the Separation. The Company entered into interest rate swap agreements and cross-currency swap agreements to manage exposures to currency exchange rates and interest rates arising from these credit facilities; refer to Note 9 “Debt” and Note 10 “Derivatives” for additional information. On May 12, 2022, ESAB declared a quarterly cash dividend of $0.05 per share of the Company’s common stock. The dividend of $3.0 million was paid to stockholders stockholders
Basis of Presentation		The accompanying Consolidated and Combined Condensed Financial Statements present the Company’s historical financial position, results of operations, changes in equity and cash flows in accordance with generally accepted accounting principles in the United States of America (“GAAP”). The combined condensed financial statements for periods prior to the Separation were derived from Enovis’s consolidated financial statements and accounting records and prepared in accordance with GAAP for the preparation of carved-out Following the Separation, the consolidated financial statements include ESAB and its wholly-owned subsidiaries and no longer include any allocations of expenses from Enovis. Accordingly: • The Consolidated Balance Sheet as of September 30, 2022, consists of the consolidated balances of ESAB, while the Combined Condensed Balance Sheet as of December 31, 2021, consists of the combined balances of the former Fabrication Technology business of Enovis. • The Consolidated and Combined Condensed Statement of Operations and Statement of Comprehensive Income for the nine months ended September 30, 2022 consist of the consolidated results of ESAB for the six months ended September 30, 2022 and the combined results of the former Fabrication Technology business of Enovis and the certain entities discussed in the “Separation from Enovis” section above for the three months ended April 1, 2022. The Combined Condensed Statement of Operations and Statement of Comprehensive Income for the three and nine months ended October 1, 2021 consist of the combined results of the former Fabrication Technology business of Enovis. • The Consolidated and Combined Condensed Statement of Changes in Equity for the nine months ended September 30, 2022 consists of the consolidated activities of ESAB for the six months ended September 30, 2022 and the combined activity of the former Fabrication Technology business of Enovis and the certain entities discussed in the “Separation from Enovis” section above for the three months ended April 1, 2022. The Combined Condensed Statements of Changes in Equity for the three and nine months ended October 1, 2021 consist of the combined activity of the former Fabrication Technology business of Enovis. • The Consolidated and Combined Condensed Statement of Cash Flows for the nine months ended September 30, 2022 consists of the consolidated activities of ESAB for the six months ended September 30, 2022 and the combined activity of ESAB and the former Fabrication Technology business of Enovis and the certain entities discussed in the “Separation from Enovis” section above for the three months ended April 1, 2022. The Combined Condensed Statement of Cash Flows for the three and nine months ended October 1, 2021 consist of the combined activity of the former Fabrication Technology business of Enovis. The Consolidated and Combined Condensed Financial Statements of ESAB for the three and nine months ended October 1, 2021 and the three months ended April 1, 2022 may not be indicative of the Company’s results had it been a separate stand- alone entity throughout the periods presented, nor are the results stated herein indicative of what the Company’s financial position, results of operations and cash flows may be in the future. Prior to the Separation, the Company was dependent on the Former Parent for all of its working capital and financing requirements under Enovis’s centralized approach to cash management and financing of its operations. With the exception of cash, cash equivalents and borrowings clearly associated with ESAB and related to the Separation, financing transactions relating to the Company during the period prior to the Separation were accounted for through the Former Parent’s investment account of the Company. Accordingly, none of Enovis’s cash, cash equivalents or debt at the corporate level has been assigned to the Company in these financial statements. Former Parent’s Investment, which included retained earnings, represented Enovis’s interest in the recorded net assets of the Company. All significant transactions between the Company and the Former Parent prior to the Separation have been included in the accompanying Financial Statements. Transactions with the Former Parent are reflected in the accompanying Consolidated and Combined Condensed Statements of Equity as “Transfers from Former Parent, net” and in the accompanying Consolidated and Combined Condensed Balance Sheets within “Former Parent’s investment”. The Consolidated and Combined Condensed Financial Statements reflect, in the opinion of management, all adjustments, which consist solely of normal recurring adjustments, necessary to present fairly the Company’s financial position and results of operations as of and for the periods indicated. Intercompany transactions and accounts are eliminated in consolidation. In addition to the factors discussed elsewhere in this Form 10-Q, (“COVID-19”). These Consolidated and Combined Condensed Financial Statements included in this quarterly report have been prepared by the Company in accordance with the rules and regulations of the Securities and Exchange Commission (“SEC”) in conformity with GAAP, for the preparation of the Consolidated and Combined Condensed Financial Statements and are unaudited. Certain financial information that is normally included in annual financial statements prepared in accordance with GAAP, but that is not required for interim reporting purposes, has been omitted. The accompanying interim Consolidated and Combined Condensed Financial Statements and the related notes should be read in conjunction with the Company’s Combined Financial Statements and related notes included in the Company’s Form 10.
Use of Estimates	Use of Estimates The Company makes certain estimates and assumptions in preparing its Consolidated Financial Statements in accordance with U.S. GAAP. These estimates and assumptions affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the Consolidated Financial Statements and the reported amounts of revenues and expenses for the period presented. Actual results may differ from those estimates.	The Company makes certain estimates and assumptions in preparing its Consolidated and Combined Condensed Financial Statements in accordance with GAAP. These estimates and assumptions affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities as of the date of the Consolidated and Combined Condensed Financial Statements and the reported amounts of revenues and expenses for the periods presented. Actual results may differ from those estimates.​​​​​​​

Revenue (Tables)

Revenue (Tables)	7 Months Ended	9 Months Ended
	Dec. 31, 2021	Sep. 30, 2022
Revenue from Contract with Customer [Abstract]
Schedule of Revenue by Major Customers by Reporting Segments	The Company disaggregates its revenue into the following product groups: For the period from (In thousands) Consumables $ 50,916 Equipment 9,005 $ 59,921	Substantially all revenue is recognized at a point in time. The Company disaggregates its revenue into the following product groups: Three Months Ended Nine Months Ended September 30, October 1, September 30, 2022 October 1, (In thousands) Equipment $ 168,633 $ 192,365 $ 547,555 $ 564,971 Consumables 451,632 413,603 1,381,798 1,238,929 Total $ 620,265 $ 605,968 $ 1,929,353 $ 1,803,900
Schedule of Allowance for Credit Losses		A summary of the activity in the Company’s allowance for credit losses included within Trade receivables in the Consolidated and Combined Condensed Balance Sheets is as follows: Nine Months Ended September 30, 2022 Balance at Beginning of Period Charged to Write-Offs Foreign Balance at (In thousands) Allowance for credit losses $ 23,912 $ 4,756 $ (4,633 ) $ (471 ) $ 23,564

Earnings per Share from Conti_2

Earnings per Share from Continuing Operations (Tables)	9 Months Ended
	Sep. 30, 2022
Earnings Per Share [Abstract]
Schedule of Earnings Per Share from Continuing Operations	The Company allocates earnings to participating securities and computed earnings per share using the two-class Three Months Ended Nine Months Ended September 30, October 1, 2021 September 30, October 1, (In thousands, except share and per share data) Computation of earnings per share from continuing operations—basic: Income from continuing operations attributable to ESAB (1) $ 53,331 $ 60,614 $ 167,938 $ 195,679 Less: distributed and undistributed earnings allocated to nonvested shares (407 ) — (1,152 ) — Income from continuing operations attributable to common $ 52,924 $ 60,614 $ 166,786 $ 195,679 Weighted-average shares of Common stock outstanding—basic 60,063,553 60,034,311 60,045,306 60,034,311 Income per share from continuing operations—basic $ 0.88 $ 1.01 $ 2.78 $ 3.26 Three Months Ended Nine Months Ended September October 1, 2021 September October 1, (In thousands, except share and per share data) Computation of earnings per share from continuing operations—diluted: Income from continuing operations attributable to common $ 52,924 $ 60,614 $ 166,786 $ 195,679 Weighted-average shares of Common stock outstanding—diluted 60,063,553 60,034,311 60,045,306 60,034,311 Net effect of potentially dilutive securities 99,668 — 80,548 — Weighted-average shares of Common stock outstanding—dilution 60,163,221 60,034,311 60,127,684 60,034,311 Net income per share from continuing operations—diluted $ 0.88 $ 1.01 $ 2.77 $ 3.26 (1) Net income from continuing operations attributable to ESAB Corporation for the respective periods is calculated using Net income from continuing operations, less Income attributable to noncontrolling interest, net of taxes, of $1.0 million and $2.7 million for the three and nine months ended Sept em

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Schedule Of Income Before Income Tax Domestic And Foreign And Components of Income Tax Expense Benefit [Table Text Block]	Income before income taxes and Income tax expense consisted of the following: For the period from May 19, 2021 to (In thousands) Income before income taxes: Domestic operations $ — Foreign operations 11,907 $ 11,907 Income tax expense: Current: Federal $ — State — Foreign 4,893 4,893 Deferred: Domestic operations — Foreign operations 146 146 $ 5,039
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	The Company’s Income tax expense differs from the amount that would be computed by applying the U.S. federal statutory rate as follows: For the period from (In thousands) Taxes calculated at the U.S. federal statutory rate $ 2,500 Effect of tax rates on international operations 1,112 Withholding taxes 1,427 Income tax expense $ 5,039
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	The significant components of deferred tax assets and liabilities are as follows: December 31, (In thousands) Deferred tax assets: Expenses currently not deductible $ 3,423 Deferred tax liabilities: Depreciation and amortization $ (8,064 ) Inventory (722 ) Total deferred tax liabilities $ (8,786 ) Total deferred tax liabilities, net $ (5,363 )

Property, Plant and Equipment_2

Property, Plant and Equipment, Net (Tables)	7 Months Ended
	Dec. 31, 2021
Property, Plant and Equipment [Abstract]
Schedule of Property, Plant and Equipment	Property, Plant and Equipment, consisted of the following: Depreciable Life December 31, (In years) (In thousands) Land n/a $ 1,459 Buildings and improvements 5-40 4,530 Machinery and equipment 3-15 8,453 14,442 Accumulated depreciation (7,073 ) $ 7,369

Inventories, Net (Tables)

Inventories, Net (Tables)	7 Months Ended	9 Months Ended
	Dec. 31, 2021	Sep. 30, 2022
Inventory Disclosure [Abstract]
Schedule of Inventory, Net	Inventories, net consisted of the following: December 31, (In thousands) Raw materials $ 6,946 Work in process 453 Finished goods 11,935 19,334 Less: allowance for excess, slow-moving and obsolete inventory (937 ) $ 18,397	Inventories, net consisted of the following: September 30, 2022 December 31, 2021 (In thousands) Raw materials $ 152,316 $ 148,376 Work in process 45,099 39,595 Finished goods 286,132 268,831 483,547 456,802 LIFO reserve (204 ) 1,129 Less: allowance for excess, slow-moving and obsolete inventory (36,812 ) (37,869 ) $ 446,531 $ 420,062

Leases (Tables)

Leases (Tables)	7 Months Ended
	Dec. 31, 2021
Leases [Abstract]
Schedule of maturity of operating lease liabilities	The following table presents the maturity of our operating lease liabilities as of December 31, 2021: December 31, (In thousands) Future lease payments by year: 2022 $ 1,090 2023 961 2024 835 2025 530 2026 551 Thereafter 5,110 Total 9,077 Less: present value discount (1,900 ) Present value of lease liabilities $ 7,177 Weighted-average remaining lease term (in years): Operating leases 11.49 Weighted-average discount rate: Operating leases 3.9 %

Accrued and Other Liabilities (

Accrued and Other Liabilities (Tables)	9 Months Ended
	Sep. 30, 2022
Accrued Liabilities [Abstract]
Schedule of Accrued and Other Liabilities	Accrued and Other liabilities in the Consolidated and Combined Condensed Balance Sheets consisted of the following: Current Noncurrent Current Noncurrent September 30, 2022 December 31, 2021 In thousands) A cc $ 57,813 $ 169,839 $ 58,920 $ 203,760 Compensation and related benefits 70,203 62,299 74,587 62,215 Asbestos liability 34,841 236,757 — — Contract liability 22,475 — 22,265 — Lease liabilit 20,323 72,060 23,110 88,777 Warranty liability 13,721 — 14,954 — Third-party commissions 14,964 — 16,130 — Restructuring liability 6,747 100 7,834 275 Other 49,316 8,326 33,309 7,918 $ 290,403 $ 549,381 $ 251,109 $ 362,945
Schedule of Product Warranty Liability	A summary of the activity in the Company’s warranty liability included in Accrued liabilities in the Company’s Consolidated and Combined Condensed Balance Sheets is as follows: Nine Months Ended September 30, 2022 October 1, 2021 (In thousands) Warranty liability, beginning of period $ 14,954 $ 14,022 Accrued warranty expense 4,367 5,661 Changes in estimates related to pre-existing 2,190 1,401 Cost of warranty service work performed (6,815 ) (5,626 ) Foreign exchange translation effect (975 ) (256 ) Warranty liability, end of period $ 13,721 $ 15,202
Schedule of Restructuring Reserve by Type of Cost	A summary of the activity in the Company’s restructuring liability included in Accrued liabilities and Other liabilities in the Consolidated and Combined Condensed Balance Sheets is as follows: Nine Months Ended September 30, 2022 Balance at Charges Payments Foreign Balance at (In thousands) Restructuring and other related charges: Americas Termination benefits (1) $ 2,044 $ 1,691 $ (2,708 ) $ (7 ) $ 1,020 Facility closure costs and other (2) 50 10,022 (10,013 ) — 59 Subtotal 2,094 11,713 (12,721 ) (7 ) 1,079 Non-cash (2) (37 ) Segment Total 11,676 EMEA & APAC Termination benefits (1) 5,774 2,622 (2,879 ) (174 ) 5,343 Facility closure costs and other (2) 241 2,331 (2,131 ) (16 ) 425 Subtotal 6,015 4,953 (5,010 ) (190 ) 5,768 Non-cash (2) — Segment Total 4,953 Total $ 8,109 16,666 $ (17,731 ) $ (197 ) $ 6,847 Non-cash (2) (37 ) Total Provision $ 16,629 (1) Includes severance and other termination benefits, including outplacement services. (2) Includes the cost of relocating associates, relocating equipment, lease termination expense and other costs in connection with the closure and optimization of facilities and product lines.

Goodwill and Intangible Assets

Goodwill and Intangible Assets (Tables)	7 Months Ended
	Dec. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of goodwill activity	The following table summarizes Goodwill activity for the period from inception (May 19, 2021) to December 31, 2021: December 31, 2021 (In thousands) Balance, May 19, 2021 $ 79,954 Impact of foreign currency translation (4,451 ) Balance, December 31, 2021 $ 75,503
Schedule of company's intangible assets, excluding goodwill	The following table summarizes the Company’s Intangible assets, excluding Goodwill: December 31, 2021 Gross Accumulated (In thousands) Indefinite-lived intangible assets Trade names $ 4,124 $ — Definite-lived intangible assets Software 1,509 (1,280 ) Acquired customer relationships 27,402 (12,432 ) $ 33,035 $ (13,712 )

Debt (Tables)

Debt (Tables)	9 Months Ended
	Sep. 30, 2022
Debt Disclosure [Abstract]
Schedule of Long-Term Debt	Long-term debt consisted of the following: September 30, 2022 (In thousands) Term loans $ 997,415 Revolving credit facilities 135,000 Long-term debt $ 1,132,415

Derivatives (Tables)

Derivatives (Tables)	7 Months Ended	9 Months Ended
	Dec. 31, 2021	Sep. 30, 2022
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Schedule of Cash Flow Hedging Instruments, Statements of Financial Performance and Financial Position, Location [Table Text Block]		The effects of designated cash flow hedges on the Company’s Consolidated and Combined Condensed Statements of Operations consisted of the following: Three Months Ended Derivative type Loss recognized in the Consolidated and Combined Condensed Statements of Operations: September 30, 2022 (In thousands) Interest rate swap agreements Interest expense (income) and other, net $ 1,045
Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]		The table below shows the fair value of the derivatives recognized in the Consolidated Balance Sheet and also the effects of designated hedges on AOCI: September 30, 2022 Designated as hedging instruments: Other Assets Total gain recognized in AOCI, net of tax (In thousands) Cross currency swap agreements $ 9,578 $ 7,421 Interest rate swap agreements 12,855 9,960 Total $ 22,433 $ 17,381
Schedule of Realized Gain (Loss) related to Derivative Instruments	The Company recognized the following in its Consolidated Financial Statements related to its derivative instruments: For the period from (In thousands) Contracts Not Designated in a Hedge Relationship: Foreign Currency Contracts Changes in unrealized gain $ 478 Realized loss $ (2,624 )	The Company recognized the following in its Consolidated and Combined Condensed Financial Statements related to its derivative instruments not designated in a hedging relationship: Three Months Ended Nine Months Ended Foreign currency contracts September 30, 2022 October 1, 2021 September 30, 2022 October 1, 2021 (In thousands) Change in unrealized gains (losses) $ 279 $ (2,374 ) $ 469 $ (6,108 ) Realized loss (1) (740 ) (1,383 ) (17,235 ) (1,472 ) (1) The nine months ended September 30, 2022 includes realized losses relating to certain corporate entities contributed to ESAB Corporation which are reflected within Interest expense (income) and other, net, in the Consolidated and Combined Condensed Statements of Operations during the three months ended April 1, 2022. See Note 1, “Organization and Basis of Presentation” for additional details. These realized losses are offset by unrealized gains which are also reflected within Interest expense (income) and other, net, in the Consolidated and Combined Condensed Statements of Operations during the three months ended April 1, 2022.

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	7 Months Ended	9 Months Ended
	Dec. 31, 2021	Sep. 30, 2022
Fair Value Disclosures [Abstract]
Schedule of Assets and Liabilities Measured at Fair Value	A summary of the Company’s assets and liabilities that are measured at fair value on a recurring basis for each fair value hierarchy level for the periods presented is as follows: December 31, 2021 Level Level Level Total (In thousands) Assets: Foreign currency contracts - not designated as hedges (1) $ — $ 509 $ — $ 509 Liabilities: Foreign currency contracts - not designated as hedges (2) $ — $ 30 $ — $ 30 (1) Included within other current assets in the Consolidated Balance Sheet. (2) Included within other accrued liabilities in the Consolidated Balance Sheet.	A summary of the Company’s assets and liabilities that are measured at fair value for each fair value hierarchy level for the periods presented is as follows: September 30, 2022 Level One Level Two Level Three Total (In thousands) Assets: Cash equivalents $ 6,633 $ — $ — $ 6,633 Foreign currency contracts—not designated as hedges (1) — 2,432 — 2,432 Cross currency swap agreements — 9,578 — 9,578 Interest rate swap agreements — 12,855 — 12,855 Deferred compensation plans — 2,189 — 2,189 $ 6,633 $ 27,054 $ — $ 33,687 Liabilities: Foreign currency contracts—not designated as hedges (2) $ — $ 2,153 $ — $ 2,153 Deferred compensation plans — 2,189 — 2,189 $ — $ 4,342 $ — $ 4,342 (1) Included within Other Current Assets in the Consolidated Balance Sheet. (2) Included within Accrued Liabilities in the Consolidated Balance Sheet. December 31, 2021 Level One Level Two Level Three Total (In thousands) Assets: Cash equivalents $ 8,133 $ — $ — $ 8,133 Foreign currency contracts—not designated as hedges (1) — 2,487 — 2,487 $ 8,133 $ 2,487 $ — $ 10,620 Liabilities: Foreign currency contracts—not designated as hedges (2) $ — $ 2,309 $ — $ 2,309 (1) Included within Other Current Assets in the Consolidated and Combined Condensed Balance Sheet. (2) Included within Accrued Liabilities in the Consolidated and Combined Condensed Balance Sheet.
Schedule of Realized Gain (Loss) related to Derivative Instruments	The Company recognized the following in its Consolidated Financial Statements related to its derivative instruments: For the period from (In thousands) Contracts Not Designated in a Hedge Relationship: Foreign Currency Contracts Changes in unrealized gain $ 478 Realized loss $ (2,624 )	The Company recognized the following in its Consolidated and Combined Condensed Financial Statements related to its derivative instruments not designated in a hedging relationship: Three Months Ended Nine Months Ended Foreign currency contracts September 30, 2022 October 1, 2021 September 30, 2022 October 1, 2021 (In thousands) Change in unrealized gains (losses) $ 279 $ (2,374 ) $ 469 $ (6,108 ) Realized loss (1) (740 ) (1,383 ) (17,235 ) (1,472 ) (1) The nine months ended September 30, 2022 includes realized losses relating to certain corporate entities contributed to ESAB Corporation which are reflected within Interest expense (income) and other, net, in the Consolidated and Combined Condensed Statements of Operations during the three months ended April 1, 2022. See Note 1, “Organization and Basis of Presentation” for additional details. These realized losses are offset by unrealized gains which are also reflected within Interest expense (income) and other, net, in the Consolidated and Combined Condensed Statements of Operations during the three months ended April 1, 2022.

Equity (Tables)

Equity (Tables)	9 Months Ended
	Sep. 30, 2022
Equity [Abstract]
Schedule of Accumulated Other Comprehensive Loss	The following tables present the changes in the balances of each component of Accumulated other comprehensive loss including reclassifications out of Accumulated other comprehensive loss for the nine months ended September 30, 2022 and October 1, 2021. All amounts are net of tax and noncontrolling interest, if any. Accumulated Other Comprehensive Loss Components Net Unrecognized Pension And Other Post- Retirement Benefit Cost Foreign Currency Translation Adjustment Gains on Net Investment Hedges Gains on Cash Flow Hedges Total (In thousands) Balance at December 31, 2021 $ (21,196 ) $ (439,692 ) $ — $ — $ (460,888 ) Other comprehensive income (loss) before reclassifications: Foreign currency translation adjustment 490 (45,171 ) — — (44,681 ) Other comprehensive income (loss) before reclassifications 490 (45,171 ) — — (44,681 ) Amounts reclassified from Accumulated other comprehensive loss (1) 786 — — — 786 Amounts contributed by Former Parent (2) (50,504 ) (8,759 ) — — (59,263 ) Net current period Other comprehensive loss (49,228 ) (53,930 ) — — (103,158 ) Balance at April 1, 2022 $ (70,424 ) $ (493,622 ) $ — $ — $ (564,046 ) Other comprehensive income (loss) before reclassifications: Foreign currency translation adjustment (1,354 ) (98,789 ) — — (100,143 ) Other comprehensive income (loss) before reclassifications (1,354 ) (98,789 ) — — (100,143 ) Amounts reclassified from Accumulated other comprehensive loss (1) 770 — — — 770 Net current period Other comprehensive loss (584 ) (98,789 ) — — (99,373 ) Balance at July 1, 2022 $ (71,008 ) $ (592,411 ) $ — $ — $ (663,419 ) Other comprehensive income (loss) before reclassifications: Foreign currency translation adjustment 3,685 (108,755 ) 7,421 — (97,649 ) Unrealized gain on cash flow hedges — — — 9,150 9,150 Other comprehensive income (loss) before reclassifications 3,685 (108,755 ) 7,421 9,150 (88,499 ) Amounts reclassified from Accumulated other comprehensive loss (1)(3) 766 — — 810 1,576 Net current period Other comprehensive income (loss) 4,451 (108,755 ) 7,421 9,960 (86,923 ) Balance at September 30, 2022 $ (66,557 ) $ (701,166 ) $ 7,421 $ 9,960 $ (750,342 ) (1) The amounts on this line within the Net Unrecognized Pension And Other Post-Retirement Benefit Cost column are included in the computation of net periodic benefit cost. See Note 8, “Benefit Plans” for additional details. (2) Includes unrecognized pension and other post-retirement costs and accumulated currency translation adjustments of certain entities which were part of the Corporate segment of the Former Parent and were transferred to ESAB Corporation in anticipation of the Separation. See Note 1, “Organization and Basis of Presentation” for more information on the entities contributed from the Former Parent. (3) During the three months ended September 30, 2022, the amount on this line within the Gains on Cash Flow Hedge column, is a component of Interest expense (income) and other, net . Accumulated Other Comprehensive Loss Components Net Unrecognized Pension And Other Post- Retirement Benefit Cost Foreign Currency Translation Adjustment Total (In thousands) Balance at December 31, 2020 $ (29,378 ) $ (366,825 ) $ (396,203 ) Other comprehensive income (loss) before reclassifications: Foreign currency translation adjustment 712 (30,438 ) (29,726 ) Other comprehensive income (loss) before reclassifications 712 (30,438 ) (29,726 ) Amounts reclassified from Accumulated other comprehensive loss (1) 220 — 220 Net current period Other comprehensive income (loss) 932 (30,438 ) (29,506 ) Balance at April 2, 2021 $ (28,446 ) $ (397,263 ) $ (425,709 ) Other comprehensive income (loss) before reclassifications: Foreign currency translation adjustment (126 ) 4,182 4,056 Other comprehensive income (loss) before reclassifications (126 ) 4,182 4,056 Amounts reclassified from Accumulated other comprehensive loss (1) 208 — 208 Net current period Other comprehensive income (loss) 82 4,182 4,264 Balance at July 2, 2021 $ (28,364 ) $ (393,081 ) $ (421,445 ) Other comprehensive income (loss) before reclassifications: Foreign currency translation adjustment 508 (36,639 ) (36,131 ) Other comprehensive income (loss) before reclassifications 508 (36,639 ) (36,131 ) Amounts reclassified from Accumulated other comprehensive loss (1) 270 — 270 Net current period Other comprehensive income (loss) 778 (36,639 ) (35,861 ) Balance at October 1, 2021 $ (27,586 ) $ (429,720 ) $ (457,306 ) (1) Included in the computation of net periodic benefit cost. See Note 8, “Benefit Plans” for additional details.

Commitments and Contingencies (

Commitments and Contingencies (Tables)	9 Months Ended
	Sep. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
Schedule of Loss Contingencies by Number of Claims	Asbestos-related claims activity since December 31, 2021 is as follows: Nine Months Ended September 30, 2022 (Number of claims) Claims unresolved, beginning of period 14,559 Claims filed (1) 3,285 Claims resolved (2) (3,677 ) Claims unresolved, end of period 14,167 (1) Claims filed include all asbestos claims for which notification has been received or a file has been opened. (2) Claims resolved include all asbestos claims that have been settled, dismissed or that are in the process of being settled or dismissed based upon agreements or understandings in place with counsel for the claimants.
Schedule of Asbestos Related Litigation	The Company’s Consolidated Balance Sheet included the following amounts related to asbestos-related litigation: September 30, 2022 (In thousands) Long-term asbestos insurance asset (1) $ 216,760 Long-term asbestos insurance receivable (1) 23,291 Accrued asbestos liability (2) 34,841 Long-term asbestos liability (3) 236,757 (1) Included in Other assets in the Consolidated Balance Sheet. (2) Represents current accruals for probable and reasonably estimable asbestos-related liability costs that the Company believes the subsidiaries will pay, and unpaid legal costs related to defending themselves against asbestos-related liability claims and legal action against the Company’s insurers, which is included in Accrued liabilities in the Consolidated Balance Sheet. (3) Included in Other liabilities in the Consolidated Balance Sheet.

Segment Information (Tables)

Segment Information (Tables)	9 Months Ended
	Sep. 30, 2022
Segment Reporting [Abstract]
Schedule of Segment Reporting Information, by Segment	The Company’s segment results were as follows: Three Months Ended Nine Months Ended September 30, 2022 October 1, 2021 September 30, 2022 October 1, 2021 (In thousands) Net sales: Americas $ 281,361 $ 260,005 $ 844,741 $ 739,793 EMEA & APAC 338,904 345,963 1,084,612 1,064,107 $ 620,265 $ 605,968 $ 1,929,353 $ 1,803,900 Adjusted EBITA (1) Americas $ 43,200 $ 38,627 $ 128,860 $ 102,665 EMEA & APAC 53,520 54,093 169,769 169,785 $ 96,720 $ 92,720 $ 298,629 $ 272,450 (1) The following is a reconciliation of Operating income to Adjusted EBITA: Three Months Ended Nine Months Ended September 30, 2022 October 1, 2021 September 30, 2022 October 1, 2021 (In thousands) Operating income $ 80,994 $ 78,664 $ 250,486 $ 233,165 Restructuring and other related charges 6,676 4,227 16,629 10,791 Separation costs (1) 1,834 713 8,923 819 Amortization of acquired intangibles (2) 7,216 8,934 22,523 27,130 Other (3) — 182 68 545 Adjusted EBITA $ 96,720 $ 92,720 $ 298,629 $ 272,450 (1) Includes non-recurring (2) Included within the Selling, general and administrative expense line withing the Consolidated and Combined Condensed Statements of Operations. (3) Relates to certain items included within the Interest expense (income) and other, net line within the Consolidated and Combined Condensed Statements of Operations.

Organization and Basis of Pre_3

Organization and Basis of Presentation (Details) $ / shares in Units, $ in Thousands

3 Months Ended

9 Months Ended

12 Months Ended

Oct. 14, 2022 USD ($)

Sep. 15, 2022 $ / shares

Jul. 01, 2022 USD ($)

May 12, 2022 $ / shares

Apr. 04, 2022 USD ($) shares

Mar. 21, 2022 plan

Sep. 30, 2022 USD ($)

Jul. 01, 2022 $ / shares

Apr. 01, 2022

Oct. 01, 2021 USD ($)

Sep. 30, 2022 USD ($) segment

Oct. 01, 2021 USD ($)

Dec. 31, 2021 plan

Dec. 14, 2021 shares

May 19, 2021 shares

Concentration Risk [Line Items]

Number of reportable segments | segment

2

Quarterly cash dividend declared (in dollars per share) | $ / shares

$ 0.05

$ 0.05

$ 0.05

Payment of dividends

$ 3,000

$ 3,025

$ 0

Net income

$ 52,354

$ 60,614

163,040

195,679

Research and development expense

8,000

$ 9,100

27,100

$ 28,900

Colfax [Member]

Concentration Risk [Line Items]

Common Stock, Shares Subscribed but Unissued | shares

100

ESAB International Holdings [Member]

Concentration Risk [Line Items]

Common Stock, Shares Subscribed but Unissued | shares

100

Subsequent Event

Concentration Risk [Line Items]

Payment of dividends

$ 3,000

Russia

Concentration Risk [Line Items]

Net income

7,000

14,000

Foreign currency translation adjustment losses

$ 50,000

$ 50,000

Russia | Revenues | Geographic Concentration Risk

Concentration Risk [Line Items]

Concentration risk (as a percent)

7%

6%

Russia | Assets | Geographic Concentration Risk

Concentration Risk [Line Items]

Concentration risk (as a percent)

6%

Russian Federation and Ukraine | International Conflict

Concentration Risk [Line Items]

Increase for allowances on receivables

$ 4,000

Enovis Corporation

Concentration Risk [Line Items]

Cash consideration

$ 1,200,000

ESAB Corporation | Enovis Corporation

Concentration Risk [Line Items]

Ownership (as a percent)

10%

Common Stock

Concentration Risk [Line Items]

Percentage of outstanding stock after spin-off (as a percent)

90%

90%

Common Stock | Enovis Corporation

Concentration Risk [Line Items]

Number of shares recapitalized (in shares) | shares

3

Common Stock | ESAB Corporation | Enovis Corporation

Concentration Risk [Line Items]

Number of shares received (in shares) | shares

1

Defined Benefit Plan, Unfunded Plan

Concentration Risk [Line Items]

Number of unfunded plans | plan

2

2

Discontinued Operations - Narra

Discontinued Operations - Narrative (Details) - USD ($) $ in Millions	3 Months Ended	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2022
Asbestos
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Cash used in operating activities, discontinued operations	$ 5.6	$ 19.3

Revenue - Disaggregation of Rev

Revenue - Disaggregation of Revenue (Details) - USD ($) $ in Thousands	3 Months Ended		7 Months Ended	9 Months Ended
	Sep. 30, 2022	Oct. 01, 2021	Dec. 31, 2021	Sep. 30, 2022	Oct. 01, 2021
Disaggregation of Revenue [Line Items]
Total	$ 620,265	$ 605,968	$ 59,921	$ 1,929,353	$ 1,803,900
Equipment
Disaggregation of Revenue [Line Items]
Total	168,633	192,365	9,005	547,555	564,971
Consumables
Disaggregation of Revenue [Line Items]
Total	$ 451,632	$ 413,603	$ 50,916	$ 1,381,798	$ 1,238,929

Revenue - Narrative (Details)

Revenue - Narrative (Details) $ in Millions	3 Months Ended		7 Months Ended	9 Months Ended
	Sep. 30, 2022 USD ($)	Oct. 01, 2021 USD ($)	Dec. 31, 2021 USD ($) Customer	Sep. 30, 2022 USD ($)	Oct. 01, 2021 USD ($)	Dec. 31, 2020 USD ($)
Disaggregation of Revenue [Line Items]
Contract liability			$ 22.3			$ 21.6
Revenue recognized, contract liability	$ 4.6	$ 3.1		$ 19	$ 19.4
Contract liability, one time advance payments	$ 22.5	$ 19.9		$ 22.5	$ 19.9
Number Of Customers | Customer			0
Maximum [Member]
Disaggregation of Revenue [Line Items]
Percentage Of Revenue From Contract With Customers			10%

Revenue - Allowance for Credit

Revenue - Allowance for Credit Loss Rollforward (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2022 USD ($)
Financing Receivable, Allowance for Credit Loss [Roll Forward]
Balance at Beginning of Period	$ 23,912
Charged to Expense, net	4,756
Write-Offs and Deductions	(4,633)
Foreign Currency Translation	(471)
Balance at End of Period	$ 23,564

Earnings per Share from Conti_3

Earnings per Share from Continuing Operations (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Oct. 01, 2021	Sep. 30, 2022	Oct. 01, 2021
Computation of earnings per share from continuing operations – basic
Income from continuing operations attributable to ESAB Corporation	$ 53,331	$ 60,614	$ 167,938	$ 195,679
Less: distributed and undistributed earnings allocated to nonvested shares	(407)	0	(1,152)	0
Income from continuing operations attributable to common stockholders	$ 52,924	$ 60,614	$ 166,786	$ 195,679
Weighted-average shares of common stock outstanding - basic (in shares)	60,063,553	60,034,311	60,045,306	60,034,311
Income per share from continuing operations – basic (in dollars per share)	$ 0.88	$ 1.01	$ 2.78	$ 3.26
Computation of earnings per share from continuing operations – diluted:
Net effect of potentially dilutive securities (in shares)	99,668	0	80,548	0
Net income from continuing operations attributable to noncontrolling interest, net of taxes	$ 1,000	$ 800	$ 2,700	$ 2,400
Weighted-average shares of common stock outstanding - assuming dilution (in shares)	60,163,221	60,034,311	60,127,684	60,034,311
Income per share from continuing operations – assuming dilution (in dollars per share)	$ 0.88	$ 1.01	$ 2.77	$ 3.26

Property, Plant and Equipment_3

Property, Plant and Equipment, Net - Schedule of Property, Plant and Equipment (Details) - USD ($) $ in Thousands	7 Months Ended
	Dec. 31, 2021	Sep. 30, 2022
Property, Plant and Equipment [Line Items]
Property, plant and equipment, net	$ 286,278	$ 265,185
ESAB Corporation
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	14,442
Accumulated depreciation	(7,073)
Property, plant and equipment, net	7,369
Land [Member] | ESAB Corporation
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	1,459
Building and Building Improvements [Member] | ESAB Corporation
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 4,530
Building and Building Improvements [Member] | Minimum [Member] | ESAB Corporation
Property, Plant and Equipment [Line Items]
Depreciable life	5 years
Building and Building Improvements [Member] | Maximum [Member] | ESAB Corporation
Property, Plant and Equipment [Line Items]
Depreciable life	40 years
Machinery and Equipment [Member] | ESAB Corporation
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 8,453
Machinery and Equipment [Member] | Minimum [Member] | ESAB Corporation
Property, Plant and Equipment [Line Items]
Depreciable life	3 years
Machinery and Equipment [Member] | Maximum [Member] | ESAB Corporation
Property, Plant and Equipment [Line Items]
Depreciable life	15 years

Property, Plant and Equipment_4

Property, Plant and Equipment, Net - Additional Information (Details) $ in Millions	7 Months Ended
	Dec. 31, 2021 USD ($)
Property, Plant and Equipment [Abstract]
Depreciation	$ 0.6

Income Taxes - Schedule of Inco

Income Taxes - Schedule of Income Before Income Tax Domestic and Foreign and Components of Income Tax Expense Benefit (Details) - USD ($) $ in Thousands	3 Months Ended		7 Months Ended	9 Months Ended		10 Months Ended
	Sep. 30, 2022	Oct. 01, 2021	Dec. 31, 2021	Sep. 30, 2022	Oct. 01, 2021	Oct. 31, 2021
Income before income taxes:
Domestic operations			$ 0
Foreign operations			11,907
Income before income taxes	$ 72,129	$ 78,873	11,907	$ 234,270	$ 245,121
Current:
Federal			0
State			0
Foreign			4,893
Current income tax expense			4,893
Deferred:
Domestic operations			0
Foreign operations			146
Deferred income tax expense			146
Income tax expense	$ 17,836	$ 17,441	$ 5,039	$ 63,629	$ 47,043	$ 47,000

Income Taxes - Schedule of def

Income Taxes - Schedule of deferred tax assets and Liabilities (Details) $ in Thousands	Dec. 31, 2021 USD ($)
Deferred tax assets:
Expenses currently not deductible	$ 3,423
Deferred tax liabilities:
Depreciation and amortization	(8,064)
Inventory	(722)
Total deferred tax liabilities	(8,786)
Total deferred tax liabilities, net	$ (5,363)

Income Taxes - Schedule of Effe

Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details) - USD ($) $ in Thousands	3 Months Ended		7 Months Ended	9 Months Ended		10 Months Ended
	Sep. 30, 2022	Oct. 01, 2021	Dec. 31, 2021	Sep. 30, 2022	Oct. 01, 2021	Oct. 31, 2021
Income Tax Disclosure [Abstract]
Taxes calculated at the U.S. federal statutory rate			$ 2,500
Effect of tax rates on international operations			1,112
Withholding taxes			1,427
Income tax expense	$ 17,836	$ 17,441	$ 5,039	$ 63,629	$ 47,043	$ 47,000

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Thousands	3 Months Ended		7 Months Ended	9 Months Ended		10 Months Ended
	Sep. 30, 2022	Oct. 01, 2021	Dec. 31, 2021	Sep. 30, 2022	Oct. 01, 2021	Oct. 31, 2021	May 19, 2021
Operating income	$ 72,129	$ 78,873	$ 11,907	$ 234,270	$ 245,121
Income tax expense	$ 17,836	$ 17,441	5,039	$ 63,629	$ 47,043	$ 47,000
Effective tax rate (as a percent)	24.70%	22.10%		27.20%		19.20%
Undistributed earnings of foreign subsidiaries			17,700
Unrecognized tax benefits			$ 2,900				$ 2,900
Income tax examination, Year under examination			2012
Other Noncurrent Liabilities
Unrecognized tax benefits			$ 2,900
Unrecognized tax benefits, Income tax penalties and Interest accrued			$ 800

Inventories, Net (Details)

Inventories, Net (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Raw materials	$ 152,316	$ 148,376
Work in process	45,099	39,595
Finished goods	286,132	268,831
Inventories, gross	483,547	456,802
LIFO reserve	(204)	1,129
Less: allowance for excess, slow-moving and obsolete inventory	(36,812)	(37,869)
Inventories, net	$ 446,531	$ 420,062
Percentage of inventory valued at LIFO	33%	34%
ESAB Corporation
Raw materials		$ 6,946
Work in process		453
Finished goods		11,935
Inventories, gross		19,334
Less: allowance for excess, slow-moving and obsolete inventory		(937)
Inventories, net		$ 18,397

Leases - Schedule of Maturity o

Leases - Schedule of Maturity of Operating Lease Liabilities (Details) $ in Thousands	Dec. 31, 2021 USD ($)
Future lease payments by year:
2022	$ 1,090
2023	961
2024	835
2025	530
2026	551
Thereafter	5,110
Total	9,077
Less: present value discount	(1,900)
Present value of lease liabilities	$ 7,177
Weighted-average remaining lease term (in years):
Operating leases	11 years 5 months 26 days
Weighted-average discount rate:
Operating leases	3.90%

Leases - Additional Information

Leases - Additional Information (Details) $ in Millions	7 Months Ended
	Dec. 31, 2021 USD ($)
Leases [Abstract]
Term of contract	12 months
Operating lease, expense	$ 0.7

Accrued and Other Liabilities -

Accrued and Other Liabilities - Current and Noncurrent (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Current
Accrued taxes and deferred tax liabilities	$ 57,813	$ 58,920
Compensation and related benefits	70,203	74,587
Asbestos liability	34,841	0
Contract liability	$ 22,475	22,265
Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]	Total accrued and other liabilities, Current
Lease liability	$ 20,323	23,110
Warranty liability	13,721	14,954
Third-party commissions	14,964	16,130
Restructuring liability	6,747	7,834
Other	49,316	33,309
Total accrued and other liabilities, Current	290,403	251,109
Noncurrent
Accrued taxes and deferred tax liabilities	169,839	203,760
Compensation and related benefits	62,299	62,215
Asbestos liability	236,757	0
Contract liability	$ 0	0
Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]	Total accrued and other liabilities, Noncurrent
Lease liability	$ 72,060	88,777
Warranty liability	0	0
Third-party commissions	0	0
Restructuring liability	100	275
Other	8,326	7,918
Total accrued and other liabilities, Noncurrent	$ 549,381	$ 362,945

Accrued and Other Liabilities_2

Accrued and Other Liabilities - Warranty Liability Rollforward (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2022	Oct. 01, 2021
Movement in Standard Product Warranty Accrual [Roll Forward]
Warranty liability, beginning of period	$ 14,954	$ 14,022
Accrued warranty expense	4,367	5,661
Changes in estimates related to pre-existing warranties	2,190	1,401
Cost of warranty service work performed	(6,815)	(5,626)
Foreign exchange translation effect	(975)	(256)
Warranty liability, end of period	$ 13,721	$ 15,202

Accrued and Other Liabilities_3

Accrued and Other Liabilities - Restructuring Rollforward (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2022 USD ($)
Restructuring Reserve [Roll Forward]
Balance at Beginning of Period	$ 8,109
Charges	16,666
Payments	(17,731)
Foreign Currency Translation	(197)
Balance at End of Period	6,847
Non-cash charges	(37)
Total Provision	16,629
Americas
Restructuring Reserve [Roll Forward]
Balance at Beginning of Period	2,094
Charges	11,713
Payments	(12,721)
Foreign Currency Translation	(7)
Balance at End of Period	1,079
Non-cash charges	(37)
Total Provision	11,676
EMEA & APAC
Restructuring Reserve [Roll Forward]
Balance at Beginning of Period	6,015
Charges	4,953
Payments	(5,010)
Foreign Currency Translation	(190)
Balance at End of Period	5,768
Non-cash charges	0
Total Provision	4,953
Termination benefits | Americas
Restructuring Reserve [Roll Forward]
Balance at Beginning of Period	2,044
Charges	1,691
Payments	(2,708)
Foreign Currency Translation	(7)
Balance at End of Period	1,020
Termination benefits | EMEA & APAC
Restructuring Reserve [Roll Forward]
Balance at Beginning of Period	5,774
Charges	2,622
Payments	(2,879)
Foreign Currency Translation	(174)
Balance at End of Period	5,343
Facility closure costs and other | Americas
Restructuring Reserve [Roll Forward]
Balance at Beginning of Period	50
Charges	10,022
Payments	(10,013)
Foreign Currency Translation	0
Balance at End of Period	59
Facility closure costs and other | EMEA & APAC
Restructuring Reserve [Roll Forward]
Balance at Beginning of Period	241
Charges	2,331
Payments	(2,131)
Foreign Currency Translation	(16)
Balance at End of Period	$ 425

Goodwill and Intangible Asset_2

Goodwill and Intangible Assets - Schedule of Goodwill Activity (Details) $ in Thousands	7 Months Ended
	Dec. 31, 2021 USD ($)
Balance, December 31, 2021	$ 1,532,993
ESAB Corporation
Balance, May 19, 2021	79,954
Impact of foreign currency translation	(4,451)
Balance, December 31, 2021	$ 75,503

Goodwill and Intangible Asset_3

Goodwill and Intangible Assets - Schedule of Company's Intangible Assets Excluding Goodwill (Details) $ in Thousands	Dec. 31, 2021 USD ($)
Definite-lived intangible assets
Gross Carrying Amount	$ 33,035
Accumulated Amortization	(13,712)
Software [Member]
Definite-lived intangible assets
Gross Carrying Amount	1,509
Accumulated Amortization	(1,280)
Acquired customer relationships [Member]
Definite-lived intangible assets
Gross Carrying Amount	27,402
Accumulated Amortization	(12,432)
Trade names [Member]
Indefinite-lived intangible assets
Trade names	$ 4,124

Goodwill and Intangible Asset_4

Goodwill and Intangible Assets - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended				7 Months Ended	9 Months Ended
	Sep. 30, 2022		Oct. 01, 2021		Dec. 31, 2021	Sep. 30, 2022		Oct. 01, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization expense	$ 7,216	[1]	$ 8,934	[1]	$ 1,000	$ 22,523	[1]	$ 27,130	[1]
[1]Included within the Selling, general and administrative expense line withing the Consolidated and Combined Condensed Statements of Operations.

Benefit Plans (Details)

Benefit Plans (Details) $ in Thousands		3 Months Ended		9 Months Ended		12 Months Ended
	Mar. 21, 2022 plan	Sep. 30, 2022 USD ($)	Oct. 01, 2021 USD ($)	Sep. 30, 2022 USD ($)	Oct. 01, 2021 USD ($)	Dec. 31, 2021 USD ($) plan	Apr. 01, 2022 USD ($)
Defined Benefit Plan Disclosure [Line Items]
Net plan obligations		$ 10,600		$ 10,600
Pension settlement gain		3,300	$ 0	3,300	$ 11,208
Pension Plan
Defined Benefit Plan Disclosure [Line Items]
Plan assets						$ 201,200
Projected benefit liabilities						$ 200,600
Pretax net unrecognized pension and other post-retirement benefit cost included in accumulated other comprehensive loss							$ 50,000
Net periodic benefit costs		$ 200	$ 700	600	$ 1,400
Pension Plan | United States
Defined Benefit Plan Disclosure [Line Items]
Employer contributions				800
Pension Plan | Foreign Pension Plan
Defined Benefit Plan Disclosure [Line Items]
Employer contributions				$ 3,500
Defined Benefit Plan, Unfunded Plan
Defined Benefit Plan Disclosure [Line Items]
Number of unfunded plans | plan	2					2
Defined Benefit Plan, Unfunded Plan | Pension Plan
Defined Benefit Plan Disclosure [Line Items]
Projected benefit liabilities						$ 11,700

Debt - Schedule of Long-Term De

Debt - Schedule of Long-Term Debt (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Debt Instrument [Line Items]
Long-term debt	$ 1,132,415	$ 0
Term loans | The Credit Agreement | Line of Credit
Debt Instrument [Line Items]
Long-term debt	997,415
Revolving credit facilities | The Credit Agreement | Line of Credit
Debt Instrument [Line Items]
Long-term debt	$ 135,000

Debt - Narrative (Details)

Debt - Narrative (Details)	Apr. 04, 2022 USD ($)	Jun. 30, 2024	Jun. 30, 2023	Sep. 30, 2022 USD ($)
Debt Instrument [Line Items]
Letters of credit outstanding				$ 29,400,000
Deferred financing fees				$ 3,900,000
Enovis Corporation
Debt Instrument [Line Items]
Cash consideration	$ 1,200,000,000
The Credit Agreement
Debt Instrument [Line Items]
Indebtedness incurred	$ 1,200,000,000
Weighted-average interest rate (as a percent)				3.82%
The Credit Agreement | SOFR | Minimum
Debt Instrument [Line Items]
Basis spread on variable rate (as a percent)	1.125%
The Credit Agreement | SOFR | Maximum
Debt Instrument [Line Items]
Basis spread on variable rate (as a percent)	1.75%
The Credit Agreement | Base Rate | Minimum
Debt Instrument [Line Items]
Basis spread on variable rate (as a percent)	0.125%
The Credit Agreement | Base Rate | Maximum
Debt Instrument [Line Items]
Basis spread on variable rate (as a percent)	0.75%
The Credit Agreement | Line of Credit
Debt Instrument [Line Items]
Maximum total leverage ratio				4
Minimum interest coverage ratio				3
The Credit Agreement | Line of Credit | Scenario, Forecast
Debt Instrument [Line Items]
Maximum total leverage ratio		3.5	3.75
Revolving credit facilities | The Credit Agreement | Line of Credit
Debt Instrument [Line Items]
Aggregate principal amount	$ 750,000,000
Proceeds from revolving facility	200,000,000
Capacity for additional indebtedness				$ 615,000,000
Deferred financing fees				1,300,000
Term loans | The Credit Agreement | Senior Notes
Debt Instrument [Line Items]
Principal amount	$ 600,000,000
Debt term	364 days
Indebtedness incurred	$ 600,000,000
Term loans | The Credit Agreement | Line of Credit
Debt Instrument [Line Items]
Principal amount	400,000,000
Indebtedness incurred	400,000,000
Deferred financing fees				2,600,000
Letter of Credit
Debt Instrument [Line Items]
Aggregate principal amount				107,500,000
Letter of Credit | The Credit Agreement | Line of Credit
Debt Instrument [Line Items]
Aggregate principal amount	300,000,000
Letter of Credit | Uncommitted Credit Line
Debt Instrument [Line Items]
Aggregate principal amount				$ 50,000,000
Bridge Loan | The Credit Agreement | Line of Credit
Debt Instrument [Line Items]
Aggregate principal amount	$ 50,000,000

Derivatives - Schedule Of Cash

Derivatives - Schedule Of Cash Flow Hedging Instruments Statements Of Financial Performance And Financial Position Location (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Oct. 01, 2021	Sep. 30, 2022	Oct. 01, 2021
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Interest Expense	$ 12,165	$ (209)	$ 19,516	$ (748)
Cash Flow Hedging [Member] | Designated as Hedging Instrument [Member] | Interest rate swap agreements
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Interest Expense	$ 1,045

Derivatives - Schedule Of Deriv

Derivatives - Schedule Of Derivative Instruments In Statement Of Financial Position Fair Value (Details) - Designated as Hedging Instrument [Member] $ in Thousands	Sep. 30, 2022 USD ($)
Derivatives, Fair Value [Line Items]
Derivative, Fair Value, Net	$ 17,381
Cross Currency Interest Rate Contract [Member]
Derivatives, Fair Value [Line Items]
Derivative, Fair Value, Net	7,421
Interest Rate Swap [Member]
Derivatives, Fair Value [Line Items]
Derivative, Fair Value, Net	9,960
Other Assets [Member]
Derivatives, Fair Value [Line Items]
Derivative, Fair Value, Net	22,433
Other Assets [Member] | Cross Currency Interest Rate Contract [Member]
Derivatives, Fair Value [Line Items]
Derivative, Fair Value, Net	9,578
Other Assets [Member] | Interest Rate Swap [Member]
Derivatives, Fair Value [Line Items]
Derivative, Fair Value, Net	$ 12,855

Derivatives - Schedule of Gain

Derivatives - Schedule of Gain (Loss) on Derivative Instruments (Details) - Foreign Currency Contracts - Not Designated As Hedging Instrument - USD ($) $ in Thousands	3 Months Ended				7 Months Ended	9 Months Ended
	Sep. 30, 2022		Oct. 01, 2021		Dec. 31, 2021	Sep. 30, 2022		Oct. 01, 2021
Derivative Instruments, Gain (Loss) [Line Items]
Change in unrealized gains (losses)	$ 279		$ (2,374)		$ 478	$ 469		$ (6,108)
Realized loss	$ (740)	[1]	$ (1,383)	[1]	$ (2,624)	$ (17,235)	[1]	$ (1,472)	[1]
[1]The nine months ended September 30, 2022 includes realized losses relating to certain corporate entities contributed to ESAB Corporation which are reflected within Interest expense (income) and other, net, in the Consolidated and Combined Condensed Statements of Operations during the three months ended April 1, 2022. See Note 1, “Organization and Basis of Presentation” for additional details. These realized losses are offset by unrealized gains which are also reflected within Interest expense (income) and other, net, in the Consolidated and Combined Condensed Statements of Operations during the three months ended April 1, 2022.

Derivatives - Narrative (Detail

Derivatives - Narrative (Details) € in Millions, $ in Millions		9 Months Ended
	Jul. 14, 2022 USD ($) Derivativeinstrument	Sep. 30, 2022 USD ($)	Sep. 30, 2022 EUR (€)	Jul. 22, 2022 Derivativeinstrument	Dec. 31, 2021 USD ($)
Foreign Exchange Contract [Member]
Derivative [Line Items]
Notional amount					$ 24.2
Cash Flow Hedging [Member] | Interest Rate Swap [Member]
Derivative [Line Items]
Notional amount	$ 600
Derivative, maturity	2025-04
Basis spread on variable rate (as a percent)	3.293%	1.50%	1.50%
Number of derivative instruments | Derivativeinstrument	2
Derivative, Gain on Derivative		$ 4.2
Cash Flow Hedging [Member] | Interest Rate Swap [Member] | Maximum [Member]
Derivative [Line Items]
Basis spread on variable rate (as a percent)	1.75%
Cash Flow Hedging [Member] | Interest Rate Swap [Member] | Minimum [Member]
Derivative [Line Items]
Basis spread on variable rate (as a percent)	1.125%
Net Investment Hedging [Member] | Cross Currency Interest Rate Contract [Member]
Derivative [Line Items]
Notional amount		$ 275	€ 270
Derivative, maturity		2025-04
Number of derivative instruments | Derivativeinstrument				2
Not Designated as Hedging Instrument [Member] | Foreign Exchange Contract [Member]
Derivative [Line Items]
Notional amount		$ 183.1			$ 180.8

Fair Value Measurements - Fair

Fair Value Measurements - Fair Value Hierarchy (Details) - USD ($) $ in Thousands		Sep. 30, 2022		Dec. 31, 2021
Assets:
Cash equivalents		$ 6,633		$ 8,133
Deferred compensation plans		2,189
Total assets at fair value		33,687		10,620
Liabilities:
Deferred compensation plans		2,189
Total liabilities at fair value		4,342
Foreign currency contracts - not designated as hedges | Not Designated As Hedging Instrument
Assets:
Derivative assets		2,432	[1]	2,487	[2]
Liabilities:
Foreign currency contracts - not designated as hedges		2,153	[3]	2,309	[4]
Foreign currency contracts - not designated as hedges | Not Designated As Hedging Instrument | Fair Value, Recurring [Member]
Assets:
Foreign currency contracts - not designated as hedges	[1]			509
Liabilities:
Foreign currency contracts - not designated as hedges	[5]			30
Cross currency swap agreements
Assets:
Derivative assets		9,578
Interest rate swap agreements
Assets:
Derivative assets		12,855
Level One
Assets:
Cash equivalents		6,633		8,133
Deferred compensation plans		0
Total assets at fair value		6,633		8,133
Liabilities:
Deferred compensation plans		0
Total liabilities at fair value		0
Level One | Foreign currency contracts - not designated as hedges | Not Designated As Hedging Instrument
Assets:
Derivative assets		0	[1]	0	[2]
Liabilities:
Foreign currency contracts - not designated as hedges		0	[3]	0	[4]
Level One | Foreign currency contracts - not designated as hedges | Not Designated As Hedging Instrument | Fair Value, Recurring [Member]
Assets:
Foreign currency contracts - not designated as hedges	[1]			0
Liabilities:
Foreign currency contracts - not designated as hedges	[5]			0
Level One | Cross currency swap agreements
Assets:
Derivative assets		0
Level One | Interest rate swap agreements
Assets:
Derivative assets		0
Level Two
Assets:
Cash equivalents		0		0
Deferred compensation plans		2,189
Total assets at fair value		27,054		2,487
Liabilities:
Deferred compensation plans		2,189
Total liabilities at fair value		4,342
Level Two | Foreign currency contracts - not designated as hedges | Not Designated As Hedging Instrument
Assets:
Derivative assets		2,432	[1]	2,487	[2]
Liabilities:
Foreign currency contracts - not designated as hedges		2,153	[3]	2,309	[4]
Level Two | Foreign currency contracts - not designated as hedges | Not Designated As Hedging Instrument | Fair Value, Recurring [Member]
Assets:
Foreign currency contracts - not designated as hedges	[1]			509
Liabilities:
Foreign currency contracts - not designated as hedges	[5]			30
Level Two | Cross currency swap agreements
Assets:
Derivative assets		9,578
Level Two | Interest rate swap agreements
Assets:
Derivative assets		12,855
Level Three
Assets:
Cash equivalents		0		0
Deferred compensation plans		0
Total assets at fair value		0		0
Liabilities:
Deferred compensation plans		0
Total liabilities at fair value		0
Level Three | Foreign currency contracts - not designated as hedges | Not Designated As Hedging Instrument
Assets:
Derivative assets		0	[1]	0	[2]
Liabilities:
Foreign currency contracts - not designated as hedges		0	[3]	0	[4]
Level Three | Foreign currency contracts - not designated as hedges | Not Designated As Hedging Instrument | Fair Value, Recurring [Member]
Assets:
Foreign currency contracts - not designated as hedges	[1]			0
Liabilities:
Foreign currency contracts - not designated as hedges	[5]			$ 0
Level Three | Cross currency swap agreements
Assets:
Derivative assets		0
Level Three | Interest rate swap agreements
Assets:
Derivative assets		$ 0
[1]Included within Other Current Assets in the Consolidated Balance Sheet.[2]Included within Other Current Assets in the Consolidated and Combined Condensed Balance Sheet.[3]Included within Accrued Liabilities in the Consolidated Balance Sheet.[4]Included within Accrued Liabilities in the Consolidated and Combined Condensed Balance Sheet.[5]Included within other accrued liabilities in the Consolidated Balance Sheet.

Fair Value Measurements - Narra

Fair Value Measurements - Narrative (Details) $ in Millions	Dec. 31, 2021 USD ($)
Foreign currency contracts - not designated as hedges
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative, notional amount	$ 24.2

Fair Value Measurements - Gain

Fair Value Measurements - Gain (Loss) on Derivative Instruments (Details) - Foreign Currency Contracts - Contracts Not Designated in a Hedge Relationship - USD ($) $ in Thousands	3 Months Ended				7 Months Ended	9 Months Ended
	Sep. 30, 2022		Oct. 01, 2021		Dec. 31, 2021	Sep. 30, 2022		Oct. 01, 2021
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Change in unrealized loss	$ 279		$ (2,374)		$ 478	$ 469		$ (6,108)
Realized loss	$ (740)	[1]	$ (1,383)	[1]	$ (2,624)	$ (17,235)	[1]	$ (1,472)	[1]
[1]The nine months ended September 30, 2022 includes realized losses relating to certain corporate entities contributed to ESAB Corporation which are reflected within Interest expense (income) and other, net, in the Consolidated and Combined Condensed Statements of Operations during the three months ended April 1, 2022. See Note 1, “Organization and Basis of Presentation” for additional details. These realized losses are offset by unrealized gains which are also reflected within Interest expense (income) and other, net, in the Consolidated and Combined Condensed Statements of Operations during the three months ended April 1, 2022.

Equity - Accumulated Other Comp

Equity - Accumulated Other Comprehensive Loss (Details) - USD ($) $ in Thousands		3 Months Ended
		Sep. 30, 2022		Jul. 01, 2022		Apr. 01, 2022		Oct. 01, 2021		Jul. 02, 2021		Apr. 02, 2021
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning balance						$ 2,460,735		$ (421,445)		$ (425,709)		$ (396,203)
Other comprehensive income (loss) before reclassifications		$ (88,499)		$ (100,143)		(44,681)		(36,131)		4,056		(29,726)
Foreign currency translation adjustment		(97,649)		(100,143)		(44,681)
Unrealized gain on cash flow hedges		9,150
Amounts reclassified from Accumulated other comprehensive loss		1,576	[1],[2]	770	[2]	786	[2]	270	[3]	208	[3]	220	[3]
Amounts contributed by Former Parent	[4]					(59,263)
Net current period Other comprehensive loss		(86,923)		(99,373)		(103,158)		(35,861)		4,264		(29,506)
Ending balance		1,209,185						(457,306)		(421,445)		(425,709)
Total
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning balance		(663,419)		(564,046)		(460,888)
Ending balance		(750,342)		(663,419)		(564,046)
Net Unrecognized Pension And Other Post-Retirement Benefit Cost
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning balance		(71,008)		(70,424)		(21,196)		(28,364)		(28,446)		(29,378)
Other comprehensive income (loss) before reclassifications		3,685		(1,354)		490		508		(126)		712
Foreign currency translation adjustment		3,685		(1,354)		490
Unrealized gain on cash flow hedges		0
Amounts reclassified from Accumulated other comprehensive loss		766	[1],[2]	770	[2]	786	[2]	270	[3]	208	[3]	220	[3]
Amounts contributed by Former Parent	[4]					(50,504)
Net current period Other comprehensive loss		4,451		(584)		(49,228)		778		82		932
Ending balance		(66,557)		(71,008)		(70,424)		(27,586)		(28,364)		(28,446)
Foreign Currency Translation Adjustment
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning balance		(592,411)		(493,622)		(439,692)		(393,081)		(397,263)		(366,825)
Other comprehensive income (loss) before reclassifications		(108,755)		(98,789)		(45,171)		(36,639)		4,182		(30,438)
Foreign currency translation adjustment		(108,755)		(98,789)		(45,171)
Unrealized gain on cash flow hedges		0
Amounts reclassified from Accumulated other comprehensive loss		0	[1],[2]	0	[2]	0	[2]	0	[3]	0	[3]	0	[3]
Amounts contributed by Former Parent	[4]					(8,759)
Net current period Other comprehensive loss		(108,755)		(98,789)		(53,930)		(36,639)		4,182		(30,438)
Ending balance		(701,166)		(592,411)		(493,622)		$ (429,720)		$ (393,081)		$ (397,263)
Gains on Net Investment Hedges
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning balance		0		0		0
Other comprehensive income (loss) before reclassifications		7,421		0		0
Foreign currency translation adjustment		7,421		0		0
Unrealized gain on cash flow hedges		0
Amounts reclassified from Accumulated other comprehensive loss	[2]	0	[1]	0		0
Amounts contributed by Former Parent	[4]					0
Net current period Other comprehensive loss		7,421		0		0
Ending balance		7,421		0		0
Gains on Cash Flow Hedges
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning balance		0		0		0
Other comprehensive income (loss) before reclassifications		9,150		0		0
Foreign currency translation adjustment		0		0		0
Unrealized gain on cash flow hedges		9,150
Amounts reclassified from Accumulated other comprehensive loss	[2]	810	[1]	0		0
Amounts contributed by Former Parent	[4]					0
Net current period Other comprehensive loss		9,960		0		0
Ending balance		$ 9,960		$ 0		$ 0
[1]During the three months ended September 30, 2022, the amount on this line within the Gains on Cash Flow Hedge column, is a component of Interest expense (income) and other, net. See Note 10, “Derivatives”, for additional details.[2]The amounts on this line within the Net Unrecognized Pension And Other Post-Retirement Benefit Cost column are included in the computation of net periodic benefit cost. See Note 8, “Benefit Plans” for additional details.[3]Included in the computation of net periodic benefit cost. See Note 8, “Benefit Plans” for additional details.[4]Includes unrecognized pension and other post-retirement costs and accumulated currency translation adjustments of certain entities which were part of the Corporate segment of the Former Parent and were transferred to ESAB Corporation in anticipation of the Separation. See Note 1, “Organization and Basis of Presentation” for more information on the entities contributed from the Former Parent.

Equity - Additional Information

Equity - Additional Information (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Oct. 01, 2021	Sep. 30, 2022	Oct. 01, 2021
Equity [Abstract]
Incremental stock-based compensation expense recorded as a result of equity conversion			$ 2.6
Stock-based compensation expenses	$ 4.2	$ 1.7	$ 9.5	$ 5

Commitments and Contingencies -

Commitments and Contingencies - Narrative (Details)	9 Months Ended
	Sep. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
Future claims period	15 years

Commitments and Contingencies_2

Commitments and Contingencies - Asbestos-Related Claims Activity (Details)	9 Months Ended
	Sep. 30, 2022
Loss Contingency Accrual [Roll Forward]
Claims unresolved, beginning of period	14,559
Claims filed	3,285	[1]
Claims resolved	(3,677)	[2]
Claims unresolved, end of period	14,167
[1]Claims filed include all asbestos claims for which notification has been received or a file has been opened[2]Claims resolved include all asbestos claims that have been settled, dismissed or that are in the process of being settled or dismissed based upon agreements or understandings in place with counsel for the claimants

Commitments and Contingencies_3

Commitments and Contingencies - Asbestos Litigation (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
Long-term asbestos insurance asset	$ 216,760
Long-term asbestos insurance receivable	23,291
Accrued asbestos liability	34,841
Long-term asbestos liability	$ 236,757	$ 0

Segment Information - Summary o

Segment Information - Summary of Segment Reporting Information by Segment (Details) - USD ($) $ in Thousands		3 Months Ended				7 Months Ended	9 Months Ended
		Sep. 30, 2022		Oct. 01, 2021		Dec. 31, 2021	Sep. 30, 2022		Oct. 01, 2021
Net sales		$ 620,265		$ 605,968			$ 1,929,353		$ 1,803,900
Adjusted EBITA	[1]	96,720		92,720			298,629		272,450
Operating income		80,994		78,664			250,486		233,165
Restructuring and other related charges		6,676		4,227			16,629		10,791
Separation costs	[2]	1,834		713			8,923		819
Amortization of acquired intangibles		7,216	[3]	8,934	[3]	$ 1,000	22,523	[3]	27,130	[3]
Other	[4]	0		182			68		545
Americas
Net sales		281,361		260,005			844,741		739,793
Adjusted EBITA	[1]	43,200		38,627			128,860		102,665
EMEA & APAC
Net sales		338,904		345,963			1,084,612		1,064,107
Adjusted EBITA	[1]	$ 53,520		$ 54,093			$ 169,769		$ 169,785
[1]The following is a reconciliation of Operating income to Adjusted EBITA:[2]Includes non-recurring professional fees incurred in the planning and execution of the Separation from Enovis within the Selling, general and administrative expense line within the Consolidated and Combined Condensed Statements of Operations.[3]Included within the Selling, general and administrative expense line withing the Consolidated and Combined Condensed Statements of Operations.[4]Relates to certain items included within the Interest expense (income) and other, net line within the Consolidated and Combined Condensed Statements of Operations.

Related Party Transactions - Ad

Related Party Transactions - Additional Information (Details) - USD ($) $ in Millions	3 Months Ended		7 Months Ended	9 Months Ended
	Apr. 01, 2022	Oct. 01, 2021	Dec. 31, 2021	Oct. 01, 2021
Related Party Transaction [Line Items]
Due from related parties, Noncurrent			$ 101.6
Related party transaction, Rate			0.25%
Selling, General and Administrative Expenses [Member] | Management charges [Member]
Related Party Transaction [Line Items]
Related party transaction, Selling, general and administrative expenses from transactions with related party			$ 4
Former Partner
Related Party Transaction [Line Items]
Allocated expenses	$ 6	$ 5		$ 19.6

Subsequent Events - Additional

Subsequent Events - Additional Information (Details) - USD ($) $ in Thousands			9 Months Ended		12 Months Ended
	Oct. 14, 2022	Jul. 01, 2022	Sep. 30, 2022	Oct. 01, 2021	Aug. 31, 2022
Subsequent Event [Line Items]
Dividends paid		$ 3,000	$ 3,025	$ 0
Ohio Medical, LLC [Member]
Subsequent Event [Line Items]
Business Combination, Consideration Transferred	$ 127,000
Business Acquisition, additional cash tax benefit	15,000
Business Acquisition, Pro Forma Revenue					$ 45,000
Subsequent Event
Subsequent Event [Line Items]
Dividends paid	$ 3,000